Mitochondrial fusion protein activators having inner ring-bonded carbonyl groups and methods of use thereof

Through the mitochondrial fusion protein activator bonded to the inner ring atom and carbonyl, the problems of poor pharmacokinetic properties of existing drugs in vivo and poor blood-brain barrier penetration are solved, and better pharmacokinetic properties and Blood-brain barrier penetration provides new treatments for mitochondria-related diseases.

CN118922407APending Publication Date: 2024-11-08杰拉尔德·W·多恩二世
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029907.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-06
Filing Date
2023-04-04
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing mitochondrial fusion protein activators have the problem of poor pharmacokinetic properties in vivo use, which is difficult to effectively pass through the blood-brain barrier, and the structural diversity is limited, which affects the efficacy.

Method used

Develop mitochondrial fusion protein activators containing inner ring atoms bonded to carbonyl groups, which directly bond to the carbonyl group through inner ring atoms, allowing structural diversity and large changes in linker length, improving pharmacokinetic properties, and improving the blood of the drug Brain barrier penetration.

Benefits of technology

The effective pharmacokinetic properties and blood-brain barrier allocation of mitochondrial fusion protein activators have been achieved, which improves the efficacy and stability of the drug, and provides a possibility of new targeted treatment of mitochondria-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922407A_ABST
    Figure CN118922407A_ABST
Patent Text Reader

Abstract

A composition capable of promoting activation of a mitochondrial fusion protein may include a mitochondrial fusion protein activator having a structure represented by the following formula (I): # imgabs0 #, any stereoisomer thereof, or any pharmaceutically acceptable salt thereof. G is N or CH, and A is an optionally substituted 5-or 6-membered cycloalkyl or heterocycloalkyl ring. X is (CH2) 3, OCH2CH2, CH2OCH2, CH2CH2O, Cyc, CH2Cyc, NR1 (CH2) 3, NR1OCH2CH2, NR1CH2OCH2, NR1CH2CH2O or NR1Y, R1 is H or a C1-C6 alkyl group, and Cyc is a 1, 2-cyclopropyl group, a 1, 2-cyclobutyl group, a 1, 3-cyclobutyl group, a 1, 2-cyclopentyl group, a 1, 3-cyclopentyl group, a 1, 2-cyclohexyl group, a 1, 3-cyclohexyl group or a 1, 4-cyclohexyl group. Z is (CH2) n or # imgabs1 # R2 is an optionally substituted aryl or heteroaryl group. The variable n is an integer ranging from 1 to 5, the variable n1 is an integer ranging from 0 to 4, the variable n2 is an integer ranging from 0 to 4, and n1 + n2 = n-1.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] This invention was made with government support under Grant R42NS115184 awarded by the National Institutes of Health. The government has certain rights in this invention. Background Art

[0003] Mitochondrial dysfunction may lead to various types of neurodegenerative diseases. In this regard, defective mitochondrial fusion or fission may be particularly problematic, especially when unbalanced fusion and fission lead to mitochondrial fragmentation. Many neurodegenerative diseases in which mitochondrial dysfunction is implicated include, for example, Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease.

[0004] Mitochondrial fusion is initiated by mitochondrial outer membrane-embedded mitochondrial fusion proteins (MFNs), whose extra-organellar domains extend through the cytoplasmic space to interact with their counterparts on adjacent mitochondria. Physically linked organelles produce oligomers of varying sizes. Mitochondrial fusion proteins subsequently induce mitochondrial outer membrane fusion mediated by catalytic GTPases. Aberrant mitochondrial fusion protein activity is thought to be a contributing factor to mitochondrial-based neurodegenerative diseases. For these reasons, mitochondrial fusion proteins are attractive targets for drug discovery.

[0005] Although several chemical entities have been found to target mitochondrial fusion proteins, most have not shown pharmacokinetic properties compatible with in vivo use. U.S. Patent Application Publications 2020 / 0345668 and 2020 / 0345669 describe various 6-phenylhexanamide compounds and structural variants thereof that are capable of activating mitochondrial fusion proteins, have acceptable pharmacokinetic characteristics, and exhibit a tendency to partition toward the blood-brain barrier, as demonstrated by PAMPA (passive artificial blood-brain barrier membrane permeability assay) values. BRIEF DESCRIPTION OF THE DRAWINGS

[0007] not applicable.

[0008] Detailed description

[0009] The present disclosure relates generally to mitofusin activation and, more particularly, to compositions comprising mitofusin activators containing a terminal cycloalkyl or heterocycloalkyl group wherein an internal ring atom is bonded to a carbonyl group.

[0010] As described above, various 6-phenylhexanamide compounds are potent mitochondrial fusion protein activators that may have good pharmacokinetic properties. N-(4-hydroxycyclohexyl)-6-phenylhexanamide (Formula 1) is a representative example of a mitochondrial fusion protein activator in this class of compounds.

[0011]

[0012] As described herein, there is a surprising degree of tolerance for the manner in which the cyclic portion can be bonded to the carbonyl of the mitochondrial fusion protein activator. That is, instead of bonding the cyclic portion to the carbonyl through an exocyclic nitrogen atom as in Formula 1, the cyclic portion can be directly bonded to the carbonyl through an endocyclic atom (e.g., an endocyclic nitrogen atom or an endocyclic carbon atom), while still maintaining strong mitochondrial fusion protein activation properties. It is further surprising that by bonding the cyclic portion to the carbonyl in the aforementioned manner, considerable structural diversity can be allowed in the linker attached to the carbonyl, including a variability in the length of the linker greater than that possible for the analogs of Formula 1. By bonding the carbonyl to the endocyclic atom, improved pharmacokinetic properties can be achieved in some cases.

[0013] Therefore, the present disclosure provides a composition comprising a mitochondrial fusion protein activator having a structure represented by Formula 2, any stereoisomer thereof, or any pharmaceutically acceptable salt thereof.

[0014]

[0015] In Formula 2, G is N or CH, and A is an optionally substituted 5- or 6-membered cycloalkyl or heterocycloalkyl ring. X is (CH2)3, OCH2CH2, CH2OCH2, CH2CH2O, Cyc, CH2Cyc, NR 1 (CH2)3、NR 1 OCH2CH2、NR 1 CH2OCH2、NR 1 CH2CH2O or NR 1 Cyc. R 1 is H or C1-C6 alkyl. Cyc is 1,2-cyclopropyl, 1,2-cyclobutyl, 1,3-cyclobutyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 1,2-cyclohexyl, 1,3-cyclohexyl or 1,4-cyclohexyl. Z is (CH2) n or wherein n is an integer ranging from 1 to 5, n1 is an integer ranging from 0 to 4, n2 is an integer ranging from 0 to 4, and n1+n2=n-1. In any embodiment, R 2 is an optionally substituted aryl or heteroaryl group, preferably an optionally substituted phenyl group.

[0016] In any of the embodiments herein, the variables may be selected such that when X is CH2, Cyc or CH2Cyc, G is not CH.

[0017] The 5- or 6-membered cycloalkyl or heterocycloalkyl ring or the optionally substituted aryl or heteroaryl group in Formula 2 may be optionally substituted at any position by one or more of the following groups: amine, alkylamine, amide, alkylamide, alkoxy, aryloxy, hydroxyalkyl, azo, halogen (F, Cl, Br, I), C 1-8 Alkyl, C1-C8 carbonyl (acyl), carboxylic acid or carboxylic acid ester, cyano, C 3-8 Cycloalkyl, C 3-8 Heteroaryl, C 3-8 Heterocyclic group, C6-C 10 Aryl, hydroxy, thiol, thioether, sulfoxide, sulfone and sulfonamide, some of which may be optionally further substituted with the following groups: acetamide, alkoxy, amino, azo, Br, C 1-8 Alkyl, carbonyl, carboxyl, cyano, C 3-8 Cycloalkyl, C 3-8 Heteroaryl, C 3-8 Heterocyclyl, hydroxyl, halogen (F, Cl, Br, I), indole, nitrile, phenyl, sulfoxide, sulfone, sulfonamide and / or thiophene. The heterocyclyl group may contain one or more N, O or S atoms in its ring structure. Any alkyl or cycloalkyl group may be optionally substituted with one or more heteroatoms or heteroatom-containing groups in the carbochain or ring or as a side chain group.

[0018] We can define R 2 Suitable aryl or heteroaryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, indenyl, tetrahydronaphthyl, benzofuranyl, benzothienyl, indolyl, benzopyrazolyl, coumarinyl, isocoumarinyl, isoquinolyl, pyrrolyl, pyrrolidinyl, thienyl, furanyl, thiazolyl, imidazolyl, pyrazolyl, triazolyl, quinolyl, pyrimidinyl, pyridyl, pyridone, pyrazinyl, pyridazinyl, oxazolyl, isothiazolyl, isoxazolyl, tetrazolyl, or any isomer thereof. Any of these aryl or heteroaryl groups may be optionally substituted as further specified above.

[0019] In any of the mitochondrial fusion protein activators described herein, R 2 It can be an optionally substituted phenyl group. The phenyl group can be optionally substituted with one or more of the following entities: amine, alkylamine, amide, alkylamide, alkoxy, aryloxy, hydroxyalkyl, azo, halogen (F, Cl, Br, I), C 1-8 Alkyl, C1-C8 carbonyl (acyl), carboxylic acid or carboxylic acid ester, cyano, C 3-8 Cycloalkyl, C 3-8 Heteroaryl, C 3-8Heterocyclic group, C6-C 10 The alkyl or cycloalkyl groups may be optionally substituted with one or more heteroatoms or heteroatom-containing groups in the carbochain or ring or as side chains. The optional substitutions on the phenyl group may be present at any available phenyl ring position. There may be 0, 1, 2, 3, 4 or 5 optional substitutions.

[0020] In certain examples, the 5- or 6-membered cycloalkyl or heterocycloalkyl ring may be selected from the following groups, any of which may further have an optional substitution at any ring-opening position.

[0021]

[0022]

[0023] In more specific examples, 5- or 6-membered cycloalkyl or heterocycloalkyl can be optionally substituted piperidinyl, piperazinyl, morpholinyl, pyrrolidinyl, cyclopentyl or cyclohexyl. In some or other embodiments, 5- or 6-membered cycloalkyl or heterocycloalkyl can be optionally substituted piperidinyl, piperazinyl, morpholinyl or cyclohexyl groups.

[0024] In some or other still more specific examples, G may be N, and A may represent an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group. Such a mitochondrial fusion protein activator may have a structure represented by Formula 3.

[0025]

[0026] In formula 3, J is a bond, CH(hal), C(hal)2, CHOR 3 , CHR 4 , CHNR 4 R 5 , O or NR 4 , and Q is an optional substituent, as described above. For the variables in Formula 3, hal is a halogen (F, Cl, Br, I), R 3 is H or C1-C6 alkyl, and R 4 and R 5 In still more specific examples, G may be N, and A may represent an optionally substituted piperidinyl, piperazinyl or morpholinyl group, wherein J is CH(hal), C(hal)2, CHOR 3 , CHR 4 , CHNR 4 R 5 , O or NR 4 , Q is an optional substituent, and the variables are as specified above.

[0027] In certain examples, A may represent an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group as defined in Formula 3, and X may be (CH2)3, 1,2-cyclopropyl, 1,2-cyclobutyl or 1,3-cyclobutyl, wherein Z and R 2 It may be as defined above. In certain examples, A may represent an optionally substituted piperidinyl, piperazinyl or morpholinyl group, and X may be (CH2)3, 1,2-cyclopropyl, 1,2-cyclobutyl or 1,3-cyclobutyl, wherein Z and R 2 Can be as defined above. In more specific examples of any of the aforementioned mitochondrial fusion protein activators, Z can be (CH2) n or O(CH2) n-1 , wherein n is an integer ranging from 2 to 5. In any of the aforementioned mitochondrial fusion protein activators, R 2 May represent optionally substituted phenyl.

[0028] In some examples of mitochondrial fusion protein activators defined by Formula 3, A may represent an optionally substituted piperidinyl group, wherein J is CHOR 3 or CHR 4 In still more specific examples of any of the foregoing, A can be 4-hydroxypiperidinyl.

[0029] In certain examples, A may represent an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group as defined in Formula 3, X may be OCH2CH2, CHOCH2, CH2CH2O or CH2Cyc, wherein Cyc is 1,2-cyclopropyl, 1,2-cyclobutyl or 1,3-cyclobutyl, and Z and R 2 It can be as defined above. In a more specific example of such a mitochondrial fusion protein activator, Z can be (CH2) n or O(CH2) n-1 , wherein n is an integer in the range of 2 to 5, provided that X and Z are not CH2CH2O and O(CH2) at the same time n-1 In still more specific examples of such mitochondrial fusion protein activators, A may be an optionally substituted piperidinyl group, wherein J is CHOR 3 or CHR 4 In still more specific examples of any of the foregoing, A can be 4-hydroxypiperidinyl.

[0030] In some examples, A may represent an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl as defined in Formula 3, X may be 1,2-cyclopentyl, 1,3-cyclopentyl, 1,2-cyclohexyl, 1,3-cyclohexyl or 1,4-cyclohexyl, and Z and R 2It can be as defined above. In a more specific example of such a mitochondrial fusion protein activator, Z can be (CH2) n or O(CH2) n-1 , wherein n is an integer ranging from 2 to 5. In still more specific examples of such mitochondrial fusion protein activators, A may represent an optionally substituted piperidinyl group, wherein J is CHOR 3 or CHR 4 In still more specific examples of any of the foregoing, A can be 4-hydroxypiperidinyl.

[0031] In more specific examples, the mitochondrial fusion protein activator disclosed herein may have a structure represented by any one of the following Formulae 4-6.

[0032]

[0033]

[0034] In formula 4, o is an integer ranging from 4 to 8 or preferably from 5 to 7, and in formulas 5 and 6, p is an integer ranging from 3 to 8, or from 4 to 6, or preferably from 4 to 5. Q represents one or more optional substitutions on a phenyl or 5- or 6-membered heterocyclic ring, wherein each Q (if present) can be independently selected. In some instances, a 5- or 6-membered heterocyclic ring can be an optionally substituted piperidinyl, piperazinyl or morpholinyl group. Other variables are as defined above.

[0035] In more specific examples, the mitochondrial fusion protein activator may have a structure represented by the following Formulae 7 to 14 or any stereoisomer thereof.

[0036]

[0037]

[0038]

[0039] In some examples, A may represent an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group as defined in Formula 3, and X may be NR 1 (CH2)3 or X can be NR 1 (CH2)3、NR 1 (1,2-cyclopropyl), NR 1 (1,2-cyclobutyl) or NR 1 (1,3-cyclobutyl), and Z and R 2 It can be as defined above. In a more specific example, in any of the above items, R 1It can be H. In a more specific example of such a mitochondrial fusion protein activator, Z can be (CH2) n or O(CH2) n-1 , wherein n is an integer ranging from 1 to 4. In a more specific example, X can be NR 1 (CH2)3, Z can be (CH2) n , and n is an integer in the range of 1 to 4, preferably wherein R 1 It can be H.

[0040] In still more specific examples of any of the foregoing, A may represent an optionally substituted piperidinyl group wherein J is CHOR 3 or CHR 4 In still more specific examples, A may be 4-hydroxypiperidinyl.

[0041] In some examples, A may represent an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group as defined in Formula 3, and X may be NR 1 OCH2CH2、NR 1 CH2OCH2、NR 1 CH2CH2O or NR 1 Cyc, wherein Cyc is 1,2-cyclopropyl, 1,2-cyclobutyl or 1,3-cyclobutyl, and Z and R 2 Can be as defined above. In some embodiments, in any of the foregoing, R 1 It can be H. In a more specific example of such a mitochondrial fusion protein activator, Z can be (CH2) n or O(CH2) n-1 , wherein n is an integer ranging from 1 to 4, provided that X and Z are not NR 1 CH2CH2O and O(CH2) n-1 In still more specific examples of any of the foregoing, A may represent an optionally substituted piperidinyl group, wherein J is CHOR 3 or CHR 4 In still more specific examples, A may be 4-hydroxypiperidinyl.

[0042] In some embodiments, A may represent an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group as defined in Formula 3, and X may be NR 1 (1,2-cyclopentyl), NR 1 (1,3-cyclopentyl), NR 1 (1,2-cyclohexyl), NR 1 (1,3-cyclohexyl) or NR 1 (1,4-cyclohexyl), and Z and R 2Can be as defined above. In some embodiments, in any of the foregoing, R 1 It can be H. In a more specific example of such a mitochondrial fusion protein activator, Z can be (CH2) n or O(CH2) n-1 , wherein n is an integer ranging from 1 to 4. In still more specific examples of any of the foregoing, A may represent an optionally substituted piperidinyl group, wherein J is CHOR 3 or CHR 4 In still more specific examples, A may be 4-hydroxypiperidinyl.

[0043] In more specific examples, the mitochondrial fusion protein activator disclosed herein may have a structure represented by any one of the following Formulas 15-17.

[0044]

[0045] In formula 15, o is an integer ranging from 5 to 7 or 4 to 6, and in formulas 16 and 17, p is an integer ranging from 4 to 6 or 3 to 5. Q represents one or more optional substitutions on a phenyl or 5- or 6-membered heterocyclic ring, wherein each Q (if present) can be independently selected. In some instances, a 5- or 6-membered heterocyclic ring can be an optionally substituted piperidinyl, piperazinyl or morpholinyl group. Other variables are as defined above.

[0046] In still more specific examples, the mitochondrial fusion protein activator may have a structure represented by the following Formula 18 or any stereoisomer thereof.

[0047]

[0048] In other examples of mitochondrial fusion protein activators disclosed herein, when G is CH, the 5- or 6-membered cycloalkyl or heterocycloalkyl group may be an optionally substituted piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, cyclopentyl or cyclohexyl group. Preferably, A may represent an optionally substituted cyclopentyl or cyclohexyl group. Such mitochondrial fusion protein activators may have a structure represented by Formula 19 or any stereoisomer thereof.

[0049]

[0050] In formula 19, J is a bond, CH(hal), C(hal)2, CHOR 3 , CHR 4 , CHNR 4 R 5 , O or NR 4 , and Q is an optional substituent, as described above. In Formula 19, hal is a halogen (F, Cl, Br, I), R3 is H or C1-C6 alkyl, and R 4 and R 5 is independently H, C1-C6 alkyl or C1-C6 acyl. In some embodiments, J is not a bond, O or NR 4 , so that A represents an optionally substituted cyclohexyl group. Preferably, J can be CHOR 3 or CHR 4 In some examples, A can represent a 4-hydroxycyclohexyl group, and the other variables can be as specified above.

[0051] In certain examples, A may represent an optionally substituted cyclohexyl group as defined in Formula 19, and X may be NR 1 (CH2)3、NR 1 (1,2-cyclopropyl), NR 1 (1,2-cyclobutyl) or NR 1 (1,3-cyclobutyl). In the foregoing, R 1 can be H or C1-C6 alkyl, and Z and R 2 It can be as defined above. In a more specific example of such a mitochondrial fusion protein activator, Z can be (CH2) n or O(CH2) n-1 , wherein n is an integer ranging from 2 to 4. In various examples of such mitochondrial fusion protein activators, R 1 It can be H. In some examples, X can be NR 1 (CH2)3, Z can be (CH2) n , and n is an integer ranging from 2 to 4. In some examples, X can be NR 1 (1,2-cyclopropyl), NR 1 (1,2-cyclobutyl) or NR 1 (1,3-cyclobutyl), Z can be selected from (CH2) n and O(CH2) n-1 , and n is an integer ranging from 2 to 4. In still more specific examples of any of the foregoing, A may represent an optionally substituted cyclohexyl group, wherein J is CHOR 3 or CHR 4 In still more specific examples of any of the foregoing, A can be 4-hydroxycyclohexyl.

[0052] In some examples, A may represent an optionally substituted cyclohexyl group as defined and specified in Formula 19, and X may be NR 1 OCH2CH2、NR 1 CH2OCH2 or NR 1 CH2CH2O.R 1can be H or C1-C6 alkyl, and Z and R 2 Can be as defined above. In any example of such a mitochondrial fusion protein activator, R 1 It can be H. In a more specific example of such a mitochondrial fusion protein activator, Z can be (CH2) n or O(CH2) n-1 , wherein n is an integer in the range of 2 to 4, provided that X and Z are not NR 1 CH2CH2O and O(CH2) n-1 In still more specific examples of any of the foregoing, A may represent an optionally substituted cyclohexyl group, wherein J is CHOR 3 or CHR 4 In still more specific examples of any of the foregoing, A can be 4-hydroxycyclohexyl.

[0053] In some embodiments, A may represent an optionally substituted cyclohexyl group as defined and specified above in Formula 19, and X may be NR 1 (1,2-cyclopentyl), NR 1 (1,3-cyclopentyl), NR 1 (1,2-cyclohexyl), NR 1 (1,3-cyclohexyl) or NR 1 (1,4-cyclohexyl). 1 can be H or C1-C6 alkyl, and Z and R 2 Can be as defined above. In any example of such a mitochondrial fusion protein activator, R 1 It can be H. In a more specific example of such a mitochondrial fusion protein activator, Z can be (CH2) n or O(CH2) n-1 , wherein n is an integer ranging from 2 to 4. In still more specific examples of any of the foregoing, A may represent an optionally substituted cyclohexyl group, wherein J is CHOR 3 or CHR 4 In still more specific examples of any of the foregoing, A can be 4-hydroxycyclohexyl.

[0054] In more specific examples, the mitochondrial fusion protein activator disclosed herein may have a structure represented by the following Formula 20-25.

[0055]

[0056]

[0057] In Formulas 20 and 21, o is an integer ranging from 4 to 6, and in Formulas 22-25, p is an integer ranging from 2 to 4.

[0058] In still more specific examples, the mitochondrial fusion protein activator may have a structure represented by the following Formulae 26 to 34 or any stereoisomer thereof.

[0059]

[0060]

[0061]

[0062]

[0063] Any of the aforementioned mitochondrial fusion protein activators can exist as a mixture of stereoisomers (enantiomers or diastereomers, depending on the structure), or can exist as a single enantiomer or diastereomer. Suitable techniques for resolving stereoisomers of mitochondrial fusion protein activators or suitable techniques for producing specific stereoisomers of mitochondrial fusion protein activators will be well known to those of ordinary skill in the art. In a non-limiting example, any mitochondrial fusion protein activator with variable A as a 4-hydroxypiperidine group can contain the R-enantiomer of the 4-hydroxypiperidine group.

[0064] The term "pharmaceutically acceptable salt" as used herein refers to an organic or inorganic salt of a compound of the present disclosure having a specific toxicity and / or biodistribution property. Suitable salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and / or pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)). Pharmaceutically acceptable salts can balance the charge on the parent compound by existing as a counterion. More than one counterion can be present. When multiple counterions are present, the compound may exist as mixed pharmaceutically acceptable salts.

[0065] Pharmaceutically acceptable salts and / or hydrates of mitochondrial fusion protein activators may also be present in the compositions of the present disclosure. As used herein, the term "pharmaceutically acceptable solvate" refers to the association between one or more solvent molecules and the mitochondrial fusion protein activator of the present disclosure or a salt thereof, wherein the solvate has specific toxicity and / or biodistribution properties. Examples of solvents that can form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and / or ethanolamine. As used herein, the term "pharmaceutically acceptable hydrate" refers to the mitochondrial fusion protein activator of the present disclosure or a salt thereof, which further comprises a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces, wherein the hydrate has specific toxicity and / or biodistribution properties.

[0066] The mitochondrial fusion protein activators described herein can be formulated using one or more pharmaceutically acceptable excipients (carriers) known to those of ordinary skill in the art. As used herein, the term "pharmaceutically acceptable excipient" refers to a substance or component that does not cause unacceptable loss of pharmacological activity or unacceptable adverse side effects when administered to a subject. Examples of "pharmaceutically acceptable excipients" include, but are not limited to, solvents, dispersion media, coatings, antibacterial agents, antifungal agents, isotonic agents, and absorption delaying agents, provided that any of these agents does not produce significant side effects or is incompatible with the mitochondrial fusion protein activator in the composition. Exemplary excipients are described, for example, in Remington's Pharmaceutical Sciences (AR Gennaro, Ed.), 21st edition, ISBN: 0781746736 (2005) and United States Pharmacopeia (USP 29) and National Formulary (NF 24), United States Pharmacopeial Convention, Inc, Rockville, Maryland, 2005 ("USP / NF") or later versions, and components listed in the FDA's continuously updated inactive ingredient search online database. Other useful components not described in USP / NF may also be used. Such formulations may contain a therapeutically effective amount of one or more mitochondrial fusion protein activators, optionally as salts, hydrates and / or solvates, and a suitable amount of excipients to provide a form suitable for administration to a subject.

[0067] The compositions of the present disclosure may be stable under specific storage conditions. A "stable" composition refers to a composition having sufficient stability to allow storage at a convenient temperature (e.g., from about 0°C to about 60°C or from about -20°C to about 50°C) for a commercially reasonable period of time (e.g., at least about one day, at least about one week, at least about one month, at least about three months, at least about six months, at least about one year, or at least about two years).

[0068] The compositions of the present disclosure can be tailored to suit the desired mode of administration, which can include, but are not limited to, parenteral, pulmonary, oral, topical, transdermal, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, intraocular, pulmonary, epidural, oral, vaginal, and rectal. The compositions can also be administered in combination with one or more additional agents, or with other biologically active or biologically inert agents.

[0069] Controlled release (or sustained release) compositions can be prepared to extend the activity of mitochondrial fusion protein activators and reduce the frequency of administration. Controlled release compositions can also be used to affect the time or other characteristics of the start of action, such as the plasma level of mitochondrial fusion protein activators, and therefore affect the occurrence of side effects. Controlled release compositions can be designed to initially release a certain amount of one or more mitochondrial fusion protein activators that produce the desired therapeutic effect, and gradually and continuously release the mitochondrial fusion protein activators of other amounts, to maintain the therapeutic effect level within the extended time. In order to maintain the near constant level of mitochondrial fusion protein activators in vivo, mitochondrial fusion protein activators can be released at a rate that is enough to replace the amount of experimenter's metabolism or excretion. Controlled release can be stimulated by various inducing agents (for example, pH changes, temperature changes, enzymes, water or other physiological conditions or molecules).

[0070] The agents or compositions described herein may also be used in combination with other treatment modalities, as further described below. Thus, in addition to the therapies described herein, other therapies known to be effective for treating a disease, disorder or condition targeted by a mitochondrial fusion protein activator or a related disease, disorder or condition may also be provided to the subject.

[0071] The mitochondrial fusion protein activator of the present disclosure can stimulate mitochondrial fusion, increase mitochondrial adaptability, and enhance mitochondrial subcellular transport. Therefore, in another aspect of the present disclosure, any one or combination of the mitochondrial fusion protein activator of the present disclosure or its pharmaceutically acceptable salt can be administered in a therapeutically effective amount to a subject suffering from or suspected of suffering from a mitochondrial-related disease, disorder or condition. The subject can be a human or other mammal suffering from or suspected of suffering from a mitochondrial-related disease, disorder or condition.

[0072] The mitochondrial-related disease, disorder or condition may be a genetic or non-genetic disorder, physical injury and / or chemical injury of the peripheral nervous system (PNS) or central nervous system (CNS). In some aspects, in the method of treating a disease, disorder or condition for which a mitochondrial fusion protein activator is indicated, the PNS or CNS disorder can be selected from any one or combination of the following: a chronic neurodegenerative disorder in which mitochondrial fusion, adaptation or trafficking is impaired; a disease or condition associated with mitochondrial fusion protein-1 (MFN1) or mitochondrial fusion protein-2 (MFN2) dysfunction; a disease associated with mitochondrial fragmentation, dysfunction and / or movement disorders; a degenerative neuromuscular disorder such as Charcot-Marie-Doucet disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Alzheimer's disease, Parkinson's disease, hereditary motor and sensory neuropathies, autism, autosomal dominant optic atrophy (ADOA), muscular dystrophy, Lou Gehrig's disease, cancer, mitochondrial myopathy, diabetes mellitus and deafness (DAD), Leber's hereditary optic neuropathy (LEBER), and schizophrenia. neuropathy (LHON), Leigh syndrome, subacute sclerosing encephalopathy, neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP), myoneurogenic gastrointestinal encephalopathy (MNGIE), myoclonic epilepsy with ragged red fibers (MERRF), mitochondrial myopathy, encephalomyopathy, lactic acidosis, stroke-like symptoms (MELAS), mtDNA depletion, mitochondrial neurogastrointestinal encephalopathy (MNGIE), mitochondrial myopathy with autonomic dysfunction, mitochondrial channelopathy, or pyruvate dehydrogenase complex deficiency (PDCD / PDH), diabetic neuropathy, chemotherapy-induced peripheral neuropathy, crush injury, SCI, traumatic brain injury (TBI), stroke, optic nerve injury, and / or related conditions involving axonal disconnection.

[0073] Other mitochondrial-related diseases, disorders or conditions that can be treated with the compositions disclosed herein include, but are not limited to, Alzheimer's disease, ALS, Alexander disease, Alpers' disease, Alpers-Huttenlocher syndrome, α-methylacyl-CoA racemase deficiency, Andermann syndrome, syndrome), Art syndrome, Ataxia neuropathy spectrum, Ataxia (e.g., oculomotor apraxia, autosomal dominant cerebellar ataxia, deafness, and narcolepsy), Autosomal recessive spastic ataxia of Charlevoix-Saguenay, Batten disease, Beta-propeller protein-related neurodegeneration, Cerebro-oculofacial-skeletal syndrome (COFS), Corticobasal degeneration, CLN1 disease, CLN10 disease, CLN2 disease, CLN3 disease, CLN4 disease, CLN6 disease, CLN7 disease, CLN8 disease, Cognitive impairment, Congenital analgesia and anhidrosis, Dementia, Familial encephalopathy with neuroserine inclusions, Familial English dementia, Familial Danish dementia, Fatty acid hydroxylase-related neurodegeneration, Friedreich's Ataxia, Gerstmann-Straussler-Scheinker Disease), GM2-gangliosidosis (e.g., AB variant), HMSN type 7 (e.g., with retinitis pigmentosa), Huntington disease, neuroaxonal dystrophy of infancy, ascending hereditary spastic palsy, infantile spinocerebellar ataxia, juvenile primary lateral sclerosis, Kennedy's disease, Kulu disease, Leigh disease, Marinesco- syndrome, mild cognitive impairment (MCI), mitochondrial membrane protein-related neurodegeneration, motor neuron disease, monolimbic muscular atrophy, motor neuron disease (MND), multiple system atrophy, multiple system atrophy with orthostatic hypotension (Shy-Drager Syndrome), multiple sclerosis, multiple system atrophy, neurodegeneration in Down syndrome (NDS), neurodegeneration in aging, neurodegeneration with brain iron deposition, neuromyelitis optica, pantothenate kinase-related neurodegeneration, opsoclonus-myoclonus, prion disease, progressive multifocal leukoencephalopathy, Parkinson's disease, Parkinson's disease-related diseases, multicystic lipomembranous dysplasia with sclerosing leukoencephalopathy, prion disease, progressive external ophthalmoplegia, riboflavin transporter deficiency neuronopathy, Sandhoff disease disease, spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA), striatonigral degeneration, transmissible spongiform encephalopathy (prion disease), and / or Wallerian-like degeneration.

[0074] Still other mitochondrial-related diseases, disorders, or conditions that can be treated with the compositions disclosed herein include avolition; agraphia; alcoholism; alexia; alien hand syndrome; Allan-Herndon-Dudley syndrome; alternating hemiplegia of childhood; Alzheimer's disease; amaurosis fugax; amnesia; ALS; aneurysm; Anderman syndrome; anesthesia; aphasia; apraxia; arachnoiditis; Arnold-Chiarimalformation; lack of self-perception; Asperger syndrome; ataxia; attention deficit hyperactivity disorder; atr-16 syndrome; auditory processing disorder; autism spectrum; Behcets disease; bipolar disorder; Bell's palsy; brachial plexus injury; brain damage; brain injury; brain tumor; Brody myopathy; Canavan disease disease; capgrasdelusion; carpal tunnel syndrome; causalgia; central pain syndrome; central pontine myelinolysis; centronuclear myopathy; cephalic disorder; cerebral aneurysm; cerebral arteriosclerosis; cerebral atrophy; cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); cerebral hypoplasia-neuropathy-ichthyosis-keratoderma syndrome (CEDNIK syndrome); cerebral gigantism; paralysis; cerebral vasculitis; cerebral spinal stenosis; Charcot-Marie-Doucet disease; chiari malformation; chorea; chronic fatigue syndrome; chronic inflammatory demyelinating polyneuropathy (CIDP); chronic pain; Cockayne syndrome; Coffin-Lowry syndrome syndrome; coma; complex regional pain syndrome; compressive neuropathy; congenital facial palsy; corticobasal degeneration; cranial arteritis; craniosynostosis; Creutzfeldt–Jakob disease; cumulative trauma disorder; Cushing's syndrome; cyclothymic disorder; cyclic vomiting syndrome (CVS); cytomegalovirus infection; Dandy–Walker syndrome; dawson disease; de ​​Morsier's syndrome; Dejerine–Klumpke palsy; Dejerine–Sottas disease;Delayed sleep phase syndrome; dementia; dermatomyositis; developmental ataxia; diabetic neuropathy; diffuse sclerosis; diplopia; impaired consciousness; Down syndrome; Dravet syndrome; Duchenne muscular dystrophy; dysarthria; familial dysautonomia; dyscalculia; dysgraphia; dyspraxia; dyslexia; dystonia; empty sella syndrome; encephalitis; encephalocele; encephalotrigeminal angiomatosis; fecal incontinence; enuresis; epilepsy; epilepsy-mental disability in women; erb's palsy; erythromelalgia; essential tremor; exploding head syndrome; Fabry's disease; Fahr's syndrome; syncope; familial spastic palsy; febrile seizures; Fisher syndrome; Friedreich's ataxia; fibromyalgia; Foville's syndrome syndrome; fetal alcohol syndrome; fragile x syndrome; fragile x-associated tremor / ataxia syndrome (FXTAS); Gaucher's disease; generalized epilepsy with febrile seizures plus; Gerstmann's syndrome; giant cell arteritis; giant cell inclusion disease; globoid cell leukodystrophy; gray matter heterotopia; Guillain–Barré syndrome; generalized anxiety disorder; HTLV-1-associated myelopathy; Hallervorden–Spatz syndrome; head injury; headache; hemifacial spasm; hereditary spastic paraplegia; hereditary ataxia, polyneuritic type; herpes zoster oticus; herpes zoster; Hirayama syndrome; Hirschsprung's disease; Holmes–Adie syndrome syndrome; holoprosencephaly; Huntington disease; hydrocephalus; cerebral edema; hypercortisolism; hypoxia; immune-mediated encephalomyelitis; inclusion body myositis; incontinence pigmenti; infantile refsum disease; infantile spasms; inflammatory myopathy; intracranial cysts; increased intracranial pressure; iso-dicentric 15; Joubert syndrome; Karak syndrome; Kearns–Sayre syndrome; Kinsbourne syndrome; Kleine–Levin syndrome; Klippel Feil syndrome;Krabbe disease; Kufor–Rakeb syndrome; Lafora disease; Lambert–Eaton myasthenic syndrome; Landau–Kleffner syndrome; dorsolateral medullary (Wallenberg) syndrome; learning disabilities; Leigh disease; Lennox-Gastaut syndrome; Lesch–Nyhan syndrome syndrome; leukodystrophy; leukoencephalopathy with white matter ablations; dementia with Lewy bodies; lissencephaly; locked-in syndrome; Lou Gehrig's disease (amyotrophic lateral sclerosis (ALS)); lumbar disc disease; lumbar spinal stenosis; Lyme disease - neurological sequelae; Machado-Joseph disease (spinocerebellar ataxia type 3); megalencephaly; macrocephaly; mal dedebarquement; megalencephalic leukoencephalopathy with subcortical cysts; megalencephaly; Melkersson-Rosenthal syndrome; Meniere's disease; meningitis; Menkes disease; metachromatic leukodystrophy; microcephaly; macrocephaly; migraine; Miller Fisher syndrome; mini-stroke (transient ischemic attack); misophonia; mitochondrial myopathy; mobius syndrome syndrome; monomelic muscular atrophy; Morvan syndrome; motor neuron disease - see ALS; motor skill impairment; moyamoya disease; mucopolysaccharidosis; multi-infarct dementia; multifocal motor neuropathy; multiple sclerosis; multiple system atrophy; muscular dystrophy; myalgic encephalomyelitis; myasthenia gravis; diffuse sclerosis with demyelination; infantile myoclonic encephalopathy; myoclonus; myopathy; myotubular myopathy; myotonia congenita; narcolepsy; neuro-Behcet's disease; neurofibromatosis; neuroleptic malignant syndrome; neurologic manifestations of AIDS; neurologic sequelae of lupus; neuromyotonia; neuronal ceroid lipofuscinosis; neuronal migration disorder; neuropathy; neurosis; Niemann–Pick disease disease); non-24-hour sleep-wake disorder; nonverbal learning disorder; O'Sullivan-McLeod syndrome; occipital neuralgia; occult spinal canal dysraphism;Ohtahara syndrome; olivopontocerebellar atrophy; opsoclonus-myoclonus syndrome; optic neuritis; orthostatic hypotension; otosclerosis; overuse syndrome; persistent afterimages; paresthesias; Parkinson's disease; myotonia congenita; paraneoplastic disorders; paroxysmal seizures; Parry–Romberg syndrome; pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS); Pelizaeus–Merzbacher disease; periodic paralysis; peripheral neuropathy; pervasive developmental disorder; phantom limb / pain; optic sneeze reflex; phytanic acid storage disease; Pick's disease disease; nerve pinch; pituitary tumor; pmg; polyneuropathy; poliomyelitis; polymicrogyria; polymyositis; cerebral puncta; postpolio syndrome; postherpetic neuralgia (phn); postural hypotension; Prader-Willi syndrome; primary lateral sclerosis; prion disease; progressive hemifacial atrophy; progressive multifocal leukoencephalopathy; progressive supranuclear palsy; prosopagnosia; pseudotumor cerebri; quadrantanopia; quadriplegia; rabies; radiculopathy; Ramsay Hunt syndrome type 1; Ramsay Hunt syndrome type 2; Ramsay Hunt syndrome type 3 - see Ramsay-Hunt syndrome; Rasmussen encephalitis encephalitis; reflex neurovascular dystrophy; refsum disease; REM sleep behavior disorder; repetitive stress injury; restless legs syndrome; retroviral myelopathy; Rett syndrome; Reye's syndrome; rhythmic movement dyscrasia; Romberg syndrome; Saint Vitus' dance; Sandhoff disease; Schilder's disease (two different conditions); schizencephaly; sensory processing disorder; septo-optic dysplasia; shaken baby syndrome; herpes zoster; Shy-Drobel syndrome; Sjögren's syndrome (; syndrome; sleep apnea; sleeping sickness; snatiation; Sotos syndrome; rigidity; spina bifida; spinal cord injury; spinal cord tumor; spinal muscular atrophy; spinobulbar muscular atrophy; spinocerebellar ataxia; split-brain; Steele-Richardson-Olszewski syndrome; stiff-person syndrome; stroke; Sturge–Weber syndrome syndrome; stuttering; subacute sclerosing panencephalitis; arteriosclerotic subcortical encephalopathy; superficial siderosis; Sydenham's chorea; syncope; synesthesia; syringomyelia; tarsal tunnel syndrome; tardive dyskinesia; tardive mental disorder; Tarlovcyst; Tay-Sachs disease; temporal arteritis; temporal lobe epilepsy; tetanus; tethered cord syndrome; Thomsen's disease; thoracic outlet syndrome; trigeminal neuralgia; Todd's paralysis; tourette syndrome; toxic encephalopathy; transient ischemic attack; transmissible spongiform encephalopathy; transverse myelitis; traumatic brain injury; tremor; trichotillomania; trigeminal neuralgia; tropical spastic paralysis; trypanosomiasis; tuberous sclerosis; 22q13 deletion syndrome; Unverricht-Lundborg disease disease; vestibular schwannoma (acoustic neuroma); Von Hippel-Lindau disease (VHL); viliuiskencephalomyelitis (VE); Wallenberg's syndrome; West syndrome; whiplash; Williams syndrome; Wilson's disease; Y-linked hearing loss; and / or Zellweger syndrome.

[0075] Each state, disease, disorder and condition described herein and other states, diseases, disorders and conditions can benefit from compositions and methods described herein. Generally, treating a state, disease, disorder and condition includes preventing or delaying the appearance of clinical symptoms in a mammal, which may suffer from or be susceptible to the state, disease, disorder and condition, but has not yet experienced or shown its clinical or subclinical symptoms. Treatment can also include suppressing the state, disease, disorder or condition (for example, preventing or reducing the development of disease or at least one clinical or subclinical symptom thereof). In addition, treatment can include alleviating the disease (for example, causing the disappearance of at least one of a state, disease, disorder or condition or its clinical or subclinical symptoms). The benefit to the subject to be treated can be statistically significant, or at least perceptible to the subject or doctor.

[0076] A mitochondrial-related disease, disorder or condition may be a disease primarily caused by or secondary to mitochondrial dysfunction, fragmentation or loss of fusion, or a disease associated with dysfunction of MFN1 or MFN2 catalytic activity or conformational unfolding. Mitochondrial dysfunction may be caused by genetic mutations in mitochondrial fusion proteins or other (nuclear or mitochondrial encoded) genes, or may be caused by physical, chemical or environmental insults to the CNS or PNS.

[0077] In a specific example, sensory and motor neuropathy caused by cancer chemotherapy can be prevented or treated with the compositions of the present disclosure. Chemotherapy-induced peripheral neuropathy is one of the most common complications of cancer chemotherapy, affecting 20% ​​of all patients and almost 100% of patients receiving high-dose chemotherapeutic agents. Dose-dependent neurotoxicity of motor and sensory neurons may lead to chronic pain, hypersensitivity to heat, cold and mechanical stimulation, and / or impaired neuromuscular control. The most common chemotherapeutic agents associated with CIPN are platinum, vinca alkaloids, taxanes, epothilones, and the targeted proteasome inhibitor bortezomib.

[0078] CIPN most commonly affects peripheral sensory neurons, whose cell bodies are located in dorsal root ganglia that lack the blood-brain barrier that protects other components of the central and peripheral nervous systems. Unprotected dorsal root ganglion neurons are more sensitive to neuronal overexcitation and innate immune system activation caused by circulating cytotoxic chemotherapeutic agents. CIPN affects quality of life and may be disabling because it causes chronic neuropathic pain, which, like other causes of neuralgia (e.g., post-herpetic neuralgia, diabetic mononeuropathy), is refractory to analgesic therapy. Motor nerve involvement usually manifests as loss of fine motor function, accompanied by decreased writing ability, difficulty buttoning clothes or sewing, and sometimes weakness or loss of endurance in the upper and lower limbs. CIPN usually appears within a few weeks after chemotherapy and improves after the end of chemotherapy treatment in many cases, although residual pain, sensory or motor deficits are observed in one-third to one-half of affected patients. Unfortunately, the chemotherapy dose limited by CIPN may lead to delays, reductions or interruptions in cancer treatment, thereby shortening survival.

[0079] Mitochondrial dysfunction and oxidative stress are associated with CIPN, as abnormal ultrastructural morphology, impaired mitochondrial DNA transcription and replication, induction of mitochondrial apoptotic pathways, and reduction of experimental CIPN signs by expected mitochondrial protection have been observed. Mitochondrial fusion protein activators can enhance the overall mitochondrial function of damaged neurons, increase mitochondrial transport to areas of neuronal damage, and accelerate in vitro neuronal repair / regeneration after chemotherapy-induced damage. For this reason, it is believed that mitochondrial fusion protein activators can reduce neuronal damage caused by chemotherapeutic agents in CIPN and accelerate regeneration / repair of nerves damaged by chemotherapeutic anticancer agents. Therefore, the present disclosure provides compositions and methods for treating cancer chemotherapy-induced nerve damage and neuropathy.

[0080] In another example, an injury to the CNS or PNS (e.g., trauma to the CNS or PNS, crush injury, SCI, TBI, stroke, optic nerve injury, or related conditions involving disconnection of nerve axons) can be treated with the compositions of the present disclosure. The CNS includes the brain and spinal cord, and the PNS is composed of cranial nerves, spinal nerves, and autonomic nerves connected to the CNS.

[0081] Neurological injury caused by mechanical, thermal, chemical, or ischemic factors can impair various neurological functions, such as memory, cognition, language, and voluntary movement. Most commonly, this is due to accidental compression or transection of nerve bundles or as an unintended consequence of medical interventions that interrupt normal communication between nerve cell bodies and their targets. Other types of injury may include disruption of the mutual relationship between neurons and their supporting cells or disruption of the blood-brain barrier.

[0082] Mitochondrial fusion protein activators can rapidly reverse mitochondrial dysmotility in neurons from mice or patients with various genetic or chemotherapy-induced neurodegenerative diseases, axons damaged by chemotherapeutic agents, and axons severed by physical injury. For this reason, mitochondrial fusion protein activators can enhance regeneration / repair of physically damaged nerves, such as vehicle and sports injuries, penetrating trauma caused by military or criminal acts, and iatrogenic injuries during invasive medical procedures. Therefore, the present disclosure provides compositions and methods for treating physical nerve injuries.

[0083] Mitochondrial activity is also implicated in neuropathy and traumatic crush or severed nerve injury. After a nerve tear or crush injury, the nerve will either regenerate and restore neuromuscular function, or fail to regenerate, leaving neuromuscular function permanently impaired. Mitochondrial fusion protein activators can increase mitochondrial transport, thereby enabling nerve regeneration after traumatic injury.

[0084] The amount of mitochondrial fusion protein activator and excipient used to prepare a composition of a given dosage form may vary depending on the subject to be treated, the condition to be treated, and the specific mode of administration. It should be understood that the unit content of the mitochondrial fusion protein activator contained in a single dose of a given dosage form does not necessarily constitute a therapeutically effective amount in itself, because the necessary therapeutically effective amount can be achieved by administering multiple single doses or the therapeutic effect can be accumulated over time.

[0085] Administration of the mitochondrial fusion protein activator of the present disclosure can occur as a single event or in a time course of treatment. For example, the mitochondrial fusion protein activator can be administered once a day, a week, a fortnight, or a month. For the treatment of acute conditions, the treatment time course can be at least a few days, with administration at least once a day or continuously. Certain conditions may extend treatment from a few days to a few weeks. For example, treatment can be extended for a week, two weeks, or three weeks. For chronic conditions, treatment may be extended from a few weeks to a few months or even several years.

[0086] Toxicity and therapeutic efficacy of the compositions described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals to determine the LD 50 (50% lethal dose) and ED 50 (the dose that is therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects can be expressed as the ratio LD 50 / ED 50 The therapeutic index can be as large as 100%, with larger therapeutic indices generally being understood in the art to be optimal.

[0087] Embodiments disclosed herein include

[0088] A. A composition comprising a mitochondrial fusion protein activator. The mitochondrial fusion protein activator has a structure represented by the following formula:

[0089]

[0090] Any stereoisomer thereof or any pharmaceutically acceptable salt thereof; wherein: G is N or CH, and A is an optionally substituted 5- or 6-membered cycloalkyl or heterocycloalkyl ring; X is (CH2)3, OCH2CH2, CH2OCH2, CH2CH2O, Cyc, CH2Cyc, NR 1 (CH2)3、NR 1 OCH2CH2、NR 1 CH2OCH2、NR 1 CH2CH2O or NR 1 Cyc; where R 1 is H or C1-C6 alkyl, and Cyc is 1,2-cyclopropyl, 1,2-cyclobutyl, 1,3-cyclobutyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 1,2-cyclohexyl, 1,3-cyclohexyl or 1,4-cyclohexyl; Z is (CH2) n or (CH2) n1 O(CH2) n2 ; wherein n is an integer in the range of 1 to 5, n1 is an integer in the range of 0 to 4, n2 is an integer in the range of 0 to 4, and n1+n2=n-1; and R 2 is an optionally substituted aryl or heteroaryl group.

[0091] B. A method for administering a mitochondrial fusion protein activator to a subject suffering from or suspected of having a mitochondrial-related disease. The method comprises administering a therapeutically effective amount of the composition of A, any stereoisomer thereof, or any pharmaceutically acceptable salt thereof to a subject suffering from or suspected of having a mitochondrial-related disease, disorder, or condition.

[0092] Embodiments A and B may have one or more of the following additional elements in any combination:

[0093] Element 1: R 2 is an optionally substituted phenyl group.

[0094] Element 2: wherein G is N, and A represents an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group.

[0095] Element 3: wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0096]

[0097] or any stereoisomer thereof; wherein J is a bond, CH(hal), CHOR3 , CHR 4 , CHNR 4 R 5 , O or NR 4 , and Q is an optional substituent; wherein hal is halogen, R 3 is H or C1-C6 alkyl, and R 4 and R 5 are independently H, C1-C6 alkyl or C1-C6 acyl.

[0098] Element 4: where J is CHOR 3 or CHR 4 .

[0099] Element 5: wherein X is (CH2)3, 1,2-cyclopropyl, 1,2-cyclobutyl or 1,3-cyclobutyl.

[0100] Element 6: Where Z is (CH2) n or O(CH2) n-1 , and n is an integer ranging from 2 to 5.

[0101] Element 7: wherein A is 4-hydroxypiperidinyl.

[0102] Element 8: wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0103]

[0104] 1-(4-Hydroxypiperidin-1-yl)-7-phenylheptan-1-one

[0105]

[0106] 1-(3-Hydroxypiperidin-1-yl)-7-phenylheptan-1-one,

[0107]

[0108] 1-(4-Hydroxypiperidin-1-yl)-6-phenylhexane-1-one,

[0109]

[0110] 1-(4-Hydroxypiperidin-1-yl)-8-phenyloctan-1-one,

[0111]

[0112] (4-Hydroxypiperidin-1-yl)(2-(4-phenylbutyl)cyclopropyl)methanone,

[0113]

[0114] (4-Hydroxypiperidin-1-yl)(2-(5-phenylpentyl)cyclopropyl)methanone,

[0115]

[0116] (4-Hydroxypiperidin-1-yl)(3-(4-phenylbutyl)cyclobutyl)methanone,

[0117]

[0118] (4-Hydroxypiperidin-1-yl)(3-(5-phenylpentyl)cyclobutyl)methanone

[0119] or any stereoisomer thereof.

[0120] Factor 9: Where X is NR 1 (CH2)3、NR 1 (1,2-cyclopropyl), NR 1 (1,2-cyclobutyl) or NR 1 (1,3-cyclobutyl).

[0121] Element 10: Where Z is (CH2) n or O(CH2) n-1 , and n is an integer ranging from 1 to 4.

[0122] Element 11: wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0123]

[0124] 4-Hydroxy-N-(5-phenylpentyl)piperidine-1-carboxamide

[0125] or any stereoisomer thereof.

[0126] Element 12: wherein G is CH, and A represents an optionally substituted piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, cyclopentyl or cyclohexyl group.

[0127] Element 13: wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0128]

[0129] or any stereoisomer thereof; wherein J is a bond, CH(hal), CHOR 3 , CHR 4 , CHNR 4 R 5 , O or NR 4 , and Q is an optional substituent; wherein hal is halogen, R3 is H or C1-C6 alkyl, and R 4 and R 5 are independently H, C1-C6 alkyl or C1-C6 acyl.

[0130] Element 14: Where Z is (CH2) n or O(CH2) n-1 , and n is an integer ranging from 2 to 4.

[0131] Element 15: wherein A is 4-hydroxycyclohexyl.

[0132] Element 16: wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0133]

[0134] 4-Hydroxy-N-(5-phenylpentyl)cyclohexane-1-carboxamide,

[0135]

[0136] 4-Hydroxy-N-(6-phenylhexyl)cyclohexane-1-carboxamide,

[0137]

[0138] 4-Hydroxy-N-(4-phenylbutoxy)cyclohexane-1-carboxamide,

[0139]

[0140] 4-Hydroxy-N-(2-(3-phenylpropyl)cyclopropyl)cyclohexane-1-carboxamide,

[0141]

[0142] 4-Hydroxy-N-(2-(4-phenylbutyl)cyclopropyl)cyclohexane-1-carboxamide,

[0143] 4-Hydroxy-N-(3-(3-phenylpropyl)cyclobutyl)cyclohexane-1-carboxamide,

[0144] 4-Hydroxy-N-(2-phenethoxycyclopropyl)cyclohexane-1-carboxamide,

[0145]

[0146] N-(2-(Benzyloxy)cyclopropyl)-4-hydroxycyclohexane-1-carboxamide

[0147]

[0148] 4-Hydroxy-N-(2-(3-phenylpropoxy)cyclopropyl)cyclohexane-1-carboxamide,

[0149] or any stereoisomer thereof.

[0150] Element 17: wherein the composition further comprises a pharmaceutically acceptable excipient.

[0151] Element 18: wherein the mitochondrial-related disease, disorder or condition is a genetic or non-genetic disorder, physical injury and / or chemical injury of the peripheral nervous system (PNS) or central peripheral nervous system (CNS).

[0152] Element 19: wherein the PNS or CNS disorder is one or more disorders selected from the group consisting of: chronic neurodegenerative disorders in which mitochondrial fusion, adaptation and / or trafficking are impaired; diseases or disorders associated with mitochondrial fusion protein 1 (MFN1) or mitochondrial fusion protein 2 (MFN2) dysfunction; diseases associated with mitochondrial fragmentation, dysfunction and / or movement disorders; degenerative neuromuscular disorders; Charcot-Marie-Tooth; amyotrophic lateral sclerosis; Huntington's disease; Alzheimer's disease; Parkinson's disease; hereditary motor and sensory neuropathies; autism; autosomal dominant optic atrophy (ADOA); muscular dystrophy; Lou Gehrig's disease; Gehrig's disease; cancer; mitochondrial myopathy; diabetes mellitus and deafness (DAD); Leber's hereditary optic neuropathy (LHON); Leigh's syndrome; subacute sclerosing encephalopathy; neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP); myoneurogenic gastrointestinal encephalopathy (MNGIE); myoclonic epilepsy with ragged red fibers (MERRF); mitochondrial myopathy; encephalomyopathy; lactic acidosis and stroke-like symptoms (MELAS); mtDNA depletion; mitochondrial neurogastrointestinal encephalopathy (MNGIE); mitochondrial myopathy with autonomic dysfunction; mitochondrial channelopathy; pyruvate dehydrogenase complex deficiency (PDCD / PDH); diabetic neuropathy; chemotherapy-induced peripheral neuropathy; crush injury; spinal cord injury (SCI); traumatic brain injury; stroke; optic nerve injury; and / or conditions involving axonal disconnection; and any combination thereof.

[0153] As non-limiting examples, exemplary combinations suitable for A and B include, but are not limited to, 1 and 2 (or 3); 1, 3 and 4; 1 and 3-5; 1 and 8; 1, 2 and 9; 1-3 and 9; 1-3, 9 and 10; 1 and 11; 1 and 12; 1, 12 and 13; 1, 9, 12 and 13; 1, 9 and 12-14; 1 and 16; 3 and 4; 3-5; 3 and 5; 3 and 6; 3 and 7; 3 and 9; 3, 4 and 9; 3, 4, 9 and 10; 3 and 7; 12 and 13; 12 and 14; 12-14; 4, 12 and 13; 4 and 12-14; 4, 12 and 15; 12 and 15; 12, 14 and 15; and 4, 12, 14 and 15. Any of the foregoing can be further combined with 17. Additional exemplary combinations suitable for B include any of the foregoing in further combination with one or more of 17, 18, or 19.

[0154] This disclosure also refers to the following non-limiting terms:

[0155] Item 1. A composition comprising:

[0156] A mitochondrial fusion protein activator having a structure represented by the following formula:

[0157]

[0158] any stereoisomer thereof or any pharmaceutically acceptable salt thereof;

[0159] in:

[0160] G is N or CH, and A is an optionally substituted 5- or 6-membered cycloalkyl or heterocycloalkyl ring;

[0161] X is (CH2)3, OCH2CH2, CH2OCH2, CH2CH2O, Cyc, CH2Cyc, NR 1 (CH2)3、NR 1 OCH2CH2、NR 1 CH2OCH2、NR 1 CH2CH2O or NR 1 Cyc;

[0162] Where R 1 is H or C1-C6 alkyl, and Cyc is 1,2-cyclopropyl, 1,2-cyclobutyl, 1,3-cyclobutyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 1,2-cyclohexyl, 1,3-cyclohexyl or 1,4-cyclohexyl;

[0163] Z is (CH2) n or (CH2) n1 O(CH2) n2 ;

[0164] wherein n is an integer in the range of 1 to 5, n1 is an integer in the range of 0 to 4, n2 is an integer in the range of 0 to 4, and n1+n2=n-1; and

[0165] R 2 is an optionally substituted aryl or heteroaryl group.

[0166] Item 2. The composition of Item 1, wherein R 2 is an optionally substituted phenyl group.

[0167] Clause 3. The composition of Clause 1 and Clause 2 (or the composition of Clause 1) wherein G is N and A represents an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group.

[0168] Item 4. The composition of Item 3, wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0169]

[0170] or any stereoisomer thereof;

[0171] Where J is a bond, CH(hal), CHOR 3 , CHR 4 , CHNR 4 R 5 , O or NR 4 , and Q is an optional substituent;

[0172] Where hal is a halogen, R 3 is H or C1-C6 alkyl, and R 4 and R 5 are independently H, C1-C6 alkyl or C1-C6 acyl.

[0173] Item 5. The composition of Item 4, wherein J is CHOR 3 or CHR 4 .

[0174] Clause 6. The composition of any of Clauses 3-5 (or the composition of Clause 3), wherein X is (CH2)3, 1,2-cyclopropyl, 1,2-cyclobutyl or 1,3-cyclobutyl.

[0175] Clause 7. The composition of any one of Clauses 3-6 (or the composition of Clause 6), wherein Z is (CH2) n or O(CH2) n-1 , and n is an integer ranging from 2 to 5.

[0176] Clause 8. The composition of any one of Clauses 3-7 (or the composition of Clause 6), wherein A is 4-hydroxypiperidinyl.

[0177] Clause 9. The composition of any one of clauses 3-8 (or the composition of clause 6), wherein R 2 is an optionally substituted phenyl group.

[0178] Clause 10. The composition of any one of Clauses 3-9 (or the composition of Clause 3), wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0179]

[0180] 1-(4-Hydroxypiperidin-1-yl)-7-phenylheptan-1-one,

[0181]

[0182] 1-(3-Hydroxypiperidin-1-yl)-7-phenylheptan-1-one,

[0183]

[0184] 1-(4-Hydroxypiperidin-1-yl)-6-phenylhexane-1-one,

[0185]

[0186] 1-(4-Hydroxypiperidin-1-yl)-8-phenyloctan-1-one,

[0187] (4-Hydroxypiperidin-1-yl)(2-(4-phenylbutyl)cyclopropyl)methanone,

[0188]

[0189] (4-Hydroxypiperidin-1-yl)(2-(5-phenylpentyl)cyclopropyl)methanone,

[0191] (4-Hydroxypiperidin-1-yl)(3-(4-phenylbutyl)cyclobutyl)methanone,

[0192]

[0193] (4-Hydroxypiperidin-1-yl)(3-(5-phenylpentyl)cyclobutyl)methanone,

[0194] or any stereoisomer thereof.

[0195] Clause 11. The composition of any one of clauses 3-5 (or the composition of clause 3), wherein X is NR 1 (CH2)3、NR 1(1,2-cyclopropyl), NR 1 (1,2-cyclobutyl) or NR 1 (1,3-cyclobutyl).

[0196] Clause 12. The composition of any one of clauses 3-5 or 11 (or the composition of clause 11), wherein Z is (CH2) n or O(CH2) n-1 , and n is an integer ranging from 1 to 4.

[0197] Clause 13. The composition of any of Clauses 3-5, 11 or 12 (or the composition of Clause 6 or Clause 11) wherein A is 4-hydroxypiperidinyl.

[0198] Clause 14. The composition of any of clauses 3-5 or 11-13 (or the composition of clause 6 or clause 11), wherein R 2 is an optionally substituted phenyl group.

[0199] Clause 15. The composition of any one of clauses 3-5 or 11-14 (or the composition of clause 3), wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0200]

[0201] 4-Hydroxy-N-(5-phenylpentyl)piperidine-1-carboxamide

[0202] or any stereoisomer thereof.

[0203] Clause 16. A composition of Clause 1 and Clause 2 (or a composition of Clause 1) wherein G is CH and A represents an optionally substituted piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, cyclopentyl or cyclohexyl group.

[0204] Clause 17. The composition of any one of Clauses 1, 2 or 16 (or the composition of Clause 16), wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0205]

[0206] or any stereoisomer thereof.

[0207] Where J is a bond, CH(hal), CHOR 3 , CHR 4 , CHNR 4 R 5 , O or NR 4 , and Q is an optional substituent;

[0208] Where hal is a halogen, R 3is H or C1-C6 alkyl, and R 4 and R 5 are independently H, C1-C6 alkyl or C1-C6 acyl.

[0209] Clause 18. The composition of Clause 17, wherein J is CHOR 3 or CHR 4 .

[0210] Clause 19. The composition of any one of clauses 16-18 (or the composition of clause 17), wherein X is NR 1 (CH2)3、NR 1 (1,2-cyclopropyl), NR 1 (1,2-cyclobutyl) or NR 1 (1,3-cyclobutyl).

[0211] Clause 20. The composition of any one of Clauses 16-19 (or the composition of Clause 19), wherein Z is (CH2) n or O(CH2) n-1 , and n is an integer ranging from 2 to 4.

[0212] Clause 21. The composition of any of Clauses 16-20 (or the composition of Clause 19), wherein A is 4-hydroxycyclohexyl.

[0213] Clause 22. The composition of any one of clauses 16-21 (or the composition of clause 19), wherein R 2 is an optionally substituted phenyl group.

[0214] Clause 23. The composition of any one of Clauses 16-22 (or the composition of Clause 19), wherein the mitochondrial fusion protein activator has a structure represented by the following formula:

[0215]

[0216] 4-Hydroxy-N-(5-phenylpentyl)cyclohexane-1-carboxamide,

[0217]

[0218] 4-Hydroxy-N-(6-phenylhexyl)cyclohexane-1-carboxamide,

[0219]

[0220] 4-Hydroxy-N-(4-phenylbutoxy)cyclohexane-1-carboxamide,

[0221]

[0222] 4-Hydroxy-N-(2-(3-phenylpropyl)cyclopropyl)cyclohexane-1-carboxamide,

[0223]

[0224] 4-Hydroxy-N-(2-(4-phenylbutyl)cyclopropyl)cyclohexane-1-carboxamide,

[0225]

[0226] 4-Hydroxy-N-(3-(3-phenylpropyl)cyclobutyl)cyclohexane-1-carboxamide,

[0227]

[0228] 4-Hydroxy-N-(2-phenethoxycyclopropyl)cyclohexane-1-carboxamide,

[0229]

[0230] N-(2-(Benzyloxy)cyclopropyl)-4-hydroxycyclohexane-1-carboxamide,

[0231]

[0232] 4-Hydroxy-N-(2-(3-phenylpropoxy)cyclopropyl)cyclohexane-1-carboxamide,

[0233] or any stereoisomer thereof.

[0234] Clause 24. The composition of any one of Clauses 1-23 (or the composition of Clause 1), further comprising: a pharmaceutically acceptable excipient.

[0235] Clause 25. A method comprising:

[0236] A therapeutically effective amount of the composition of any one of clauses 1-24 (or the composition of any one of clauses 1-5 or 16-18), any stereoisomer thereof, or any pharmaceutically acceptable salt thereof, is administered to a subject suffering from or suspected of suffering from a mitochondrial-related disease, disorder or condition.

[0237] Clause 26. The method of Clause 25, wherein the mitochondrial-related disease, disorder or condition is a peripheral nervous system (PNS) or central nervous system (CNS) genetic or non-genetic disorder, physical injury and / or chemical injury.

[0238] Clause 27. The method of clause 26, wherein the PNS or CNS disorder is one or more disorders selected from the group consisting of: chronic neurodegenerative disorders in which mitochondrial fusion, adaptation or trafficking is impaired; diseases or disorders associated with mitochondrial fusion protein-1 (MFN1) or mitochondrial fusion protein-2 (MFN2) dysfunction; diseases associated with mitochondrial fragmentation, dysfunction and / or movement disorders; degenerative neuromuscular disorders; Charcot-Marie-Doucet disease; amyotrophic lateral sclerosis; Huntington's disease; Alzheimer's disease; Parkinson's disease; hereditary motor and sensory neuropathies; autism; autosomal dominant optic atrophy (ADOA); muscular dystrophy; Lou Gehrig's disease; cancer; mitochondrial myopathy; diabetes mellitus and deafness (DAD); Leber's hereditary optic neuropathy (LEB) neuropathy (LHON); Leigh syndrome; subacute sclerosing encephalopathy; neuropathy; ataxia; retinitis pigmentosa and ptosis (NARP); myoneurogenic gastrointestinal encephalopathy (MNGIE); myoclonus epilepsy with red ragged fibers (MERRF); mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like symptoms (MELAS); mtDNA depletion; mitochondrial neurogastrointestinal encephalopathy (MNGIE); mitochondrial myopathy with autonomic dysfunction; mitochondrial channelopathy; pyruvate dehydrogenase complex deficiency (PDCD / PDH); diabetic neuropathy; chemotherapy-induced peripheral neuropathy; crush injury; spinal cord injury (SCI); traumatic brain injury; stroke; optic nerve injury; conditions involving axonal disconnection; and any combination thereof.

[0239] In order to facilitate a better understanding of the present disclosure, the following examples of preferred or representative embodiments are given.

[0240] In no way should the following examples be construed as limiting or defining the scope of the invention. Example

[0241] HPLC analysis was performed using a Kinetex C18 column (4.6×50 mm, 5 μm, mobile phase A: 0.0375% TFA in water (v / v), B: 0.01875% TFA in acetonitrile (v / v)) at 50° C., and absorbance was measured at 200 nm.

[0242] LC-MS / MS (ESI) was performed using two systems: 1) SHIMADZU LC-MS-2020 with LABSOLUTION V5.72 analysis software and CHROMALITH@_FLASH RP-18E 25*2.0 mm column, operated at 50°C, using a PDA (220 and 254 nm) detector, acquiring data in scanning MS mode (positive mode), scanning range m / z = 100-1000, drying gas (N2) flow rate: 15 L / min, DL voltage: 120 V and Quarry DC voltage: 20 V, or 2) Agilent 1200 / G6110A instrument with Agilent ChemStation Rev. B.04.03 software and XBRIDGE C18 2.1*50mm column, operated at 40°C, using DAD (220nm) / ELSD detector, acquiring data in scanning MS mode (positive mode), scanning range m / z=100-1000, drying gas (N2) flow rate: 10L / min, 350°C, nebulizer pressure: 35psi capillary voltage: 2500 V. NMR spectroscopy was performed on BruckerAVANCE NEO 400MHz, using 5mm PABBO BB / 19F-1H / D Z-GRD probe.

[0243] Dose responses of mitochondrial fusion protein agonists for fusogenicity were performed in Mfn1- or Mfn2-deficient MEFs (Mfn1-KO or Mfn2-KO MEFs) cultured at 37°C and 5% CO2-95% air. On day 1, cells were plated at 2×10 4Cells / well were seeded in 6-well plates and compounds were added overnight at 9 concentrations (0.5 nM-10 μM in DMSO). Mitochondria were then stained with MitoTracker Orange (200 nM; M7510; Invitrogen, Carlsbad, CA, USA). Nuclei were stained with Hoescht (10 μg / ml; Invitrogen, Thermo Fisher Scientific catalog number: #H3570). Images were acquired at room temperature on a Nikon Ti confocal microscope using a 60×1.3NA oil immersion objective in Krebs-Henseleit buffer (138 NaCl, 3.7 nM KCl, 1.2 nM KH2PO4, 15 nM glucose, 20 nM HEPES pH: 7.2-7.5 and 1 mM CaCl2). For MitoTracker Orange, the laser excitation wavelength was 549 nm and the emission wavelength was 590 nm, and for Hoescht, the laser excitation wavelength was 306 nm and the emission wavelength was 405 nm. Images were analyzed using ImageJ, and fusibility was quantified as the mitochondrial aspect ratio (length / width) and indexed as the maximum response caused by compound 35, a known mitochondrial fusion protein activator. Response curves were interpolated using a sigmoidal model using Prism8 software. EC 50 Values ​​are reported as means of at least 3 independent experiments with 95% confidence limits.

[0244]

[0245] 1-(3-(5-cyclopropyl-4-phenyl-4H-1,2,4-triazol-3-yl)propyl)-3-(2-methylcyclohexyl)

[0246] Urea

[0247] In vitro pharmacokinetic analysis was performed in duplicate by WuXi AppTec Co. Ltd. (Shanghai, China) using standard methods. Plasma protein binding was measured by equilibrium dialysis; % binding = (1-[free compound in dialysate] / [total compound in retentate]) × 100. Plasma stability of 2uM compounds in clarified frozen-thawed plasma was assessed by LC-MS / MS of the supernatant after protein precipitation; 120-minute data for studies including 0, 10, 30, 60 and 120 minutes were reported. Liver microsomal stability of 1uM compounds in liver microsomes (0.5mg / ml) after 0, 5, 10, 20, 30, 60 minutes was assessed by LC / MS / MS of reaction extracts for incubation.

[0248] Passive artificial blood-brain barrier membrane permeability assay (PAMPA-BBB) was performed using 150 μL of 10 μM compound (5% DMSO) added to a PVDF membrane pre-coated with 5 μL of a 1% brain polar lipid extract (porcine) / dodecane mixture and incubated at room temperature with shaking at 300 rpm for 4 hours. Donor and acceptor samples were analyzed by LC-MS / MS.

[0249] Further experimental details of MFN activity and PAMPA are provided in U.S. Patent Applications 2020 / 0345668 and 2020 / 0345669, which are incorporated herein by reference.

[0250] Synthesis of N-(trans-4-hydroxycyclohexyl)-5-phenylpentanamide (Formula 1). The mitochondrial fusion protein activator was prepared as described in U.S. Patent Application Publication 2020 / 0345668 (incorporated herein by reference). This compound was used as a reference standard in the following activity tests.

[0251] Synthesis of 1-(4-hydroxypiperidin-1-yl)-7-phenylheptan-1-one (Formula 7).

[0252]

[0253] To a solution of 7-phenylheptanoic acid (100 mg, 484 μmol) in DMF (1.00 mL) was added HOBt (78.6 mg, 581 μmol), EDCI (139 mg, 727 μmol) and DIEA (125 mg, 969 μmol, 168 μL). Piperidin-4-ol (53.9 mg, 533 mol) was added and stirred at 25° C. for 16 hours. The mixture was purified by HPLC (column: Phenomenex Gemini-NX C18 75×30 mm×3 μm; mobile phase: [water (0.1% TFA)-ACN]; B%: 48%-58%, 7 minutes). After HPLC purification, the residue was adjusted to pH=7 with saturated sodium bicarbonate solution and extracted with EtOAc (20.0 mL×3). The combined organic layers were dried over Na2SO4, concentrated under vacuum at 40°C, and the residue was mixed with H2O (20.0 mL) and ACN (2.50 mL). The mixture was lyophilized to give the title compound (31.1 mg, 106 umol, yield 22.1%, purity 99.5%) as a yellow oil. LC-MS: Rt = 0.868 min, m / z = 290.1 ​​(M+H). HPLC: Rt = 1.983 min, purity 99.5% at 220 nm. 1H NMR:400MHz CDCl3δ:7.26-7.30(m,2H),7.16-7.19(m,3H),4.08-4.14(m,1H),3.92-3.94(m,1H),3.70-3.76(m,1H),3.14-3.23(m, 2H),2.59-2.63(m,2H),2.30-2.34(m,2H),1.86-1.89(m,2H),1.55-1.62(m,4H),1.46-1.53(m,2H),1.35-1.39(m,4H). 13 C NMR: 400MHz CDCl3δ: (171,142,128,125,77.3,77.2,76.7,67.3,42.8,38.8,35.8,34.6,34.0,33.3,31.3,29.3,29.0,25.3)ppm.

[0254] Synthesis of 1-(3-hydroxypiperidin-1-yl)-7-phenylheptan-1-one (Formula 8).

[0255]

[0256] To a solution of 7-phenylheptanoic acid (100 mg, 484 μmol) in DMF (1.00 mL) was added HOBt (78.6 mg, 581 μmol), EDCI (139 mg, 727 μmol) and DIEA (125 mg, 969 μmol, 168 μL). Piperidin-3-ol (53.9 mg, 533 μmol) was added to the mixture and stirred at 25° C. for 16 hours. The mixture was then purified by HPLC (column: Phenomenex Gemini-NXC18 75×30 mm×3 um; mobile phase: [water (0.1% TFA)-ACN]; B%: 48%-58%, 7 minutes). The residue was adjusted to pH=7 with saturated sodium bicarbonate solution and extracted with EtOAc (20.0 mL×3). The combined organic layers were dried over Na2SO4, concentrated under vacuum at 45°C, and mixed with H2O (20.0 mL) and ACN (2.50 mL). The mixture was lyophilized to give the title compound (35.5 mg, 121 μmol, 25.2% yield, 99.4% purity) as a light yellow oil. LC-MS: Rt = 0.876 min, m / z = 290.2 (M+H)-. HPLC: Rt = 2.018 min, 99.4% purity at 220 nm. 1H NMR:400MHz MeOD-d4δ:7.20-7.28(m,2H),7.10-7.18(m,3H),3.62-3.70(m,2H),3.23-3.29(m,1H),3.15-3.21(m,1 H), 2.60 (t, J = 7.6Hz, 2H), 2.35-2.40 (m, 2H), 1.90-1.95 (m, 1H), 1.75-1.83 (m, 1H), 1.36-1.64 (m, 11H). 13 C NMR: 400MHz MeOD-d4δ: (174,144,129,126,67.3,53.7,47.3,43.3,36.9,34.3,33.8,33.5,32.7,30.4,30.2,26.6,24.7,23.3)ppm.

[0257] Synthesis of 1-(4-hydroxypiperidin-1-yl)-6-phenylhexane-1-one (Formula 9).

[0258]

[0259] To a solution of 6-phenylhexanoic acid (100 mg, 520 μmol, 98.0 μL) in DMF (1.00 mL) were added HOBt (84.3 mg, 624 μmol), DIEA (134 mg, 1.04 mmol, 181 μL), EDCI (150 mg, 780 μmol) and piperidin-4-ol (57.9 mg, 572 μmol). The mixture was stirred at 30° C. for 16 hours and purified by HPLC (column: Phenomenex Gemini-NX C18 75×30 mm×3 um; mobile phase: [water (0.1% TFA)-ACN]; B%: 38%-48%, 7 minutes). The residue was adjusted to pH=7 with saturated sodium bicarbonate solution and extracted with EtOAc (20.0 mL×3). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to give a residue, which was mixed with H2O (15 mL) and ACN (5.0 mL). The mixture was lyophilized to give the title compound (49.2 mg, 178 μmol, 34.3% yield, 99.8% purity) as a white solid. LC-MS: Rt = 0.836 min, m / z = 276.1 (M+H). HPLC: Rt = 1.854 min, 99.8% purity at 220 nm. 1H NMR: 400MHz CDCl3δ: 7.27-7.31(m,2H),7.18-7.20(m,3H),4.09-4.13(m,1H),3.92-3.95(m,1H),3.71-3.91(m,1H),3.17-3. 21(m,2H),2.61-2.65(m,2H),2.31-2.35(m,2H),1.87-1.89(m,3H),1.67-1.69(m,4H),1.64-1.65(m,2H),1.40-1.42(m,2H). 13 C NMR: 400MHz CDCl3δ: (171,143,128,126,67.2,42.8,38.9,35.7,34.6,33.9,33.2,31.2,29.1,25.2)ppm.

[0260] Synthesis of 1-(4-hydroxypiperidin-1-yl)-8-phenyloctan-1-one (Formula 10).

[0261]

[0262] To a solution of 8-phenyloctanoic acid (100 mg, 453 μmol) in DMF (1.00 mL) were added HOBt (73.6 mg, 544.6 μmol), EDCI (130 mg, 680 μmol), DIEA (117 mg, 907 μmol, 158 μL) and piperidin-4-ol (53.9 mg, 533 μmol). The mixture was stirred at 30° C. for 3.5 hours and purified by HPLC (column: Phenomenex Gemini-NX C18 75×30 mm×3 μm; mobile phase: [water (0.1% TFA)-ACN]; B%: 52%-62%, 7 min). The residue was adjusted to pH=7 with saturated sodium bicarbonate solution and extracted with EtOAc (20 mL×3). The combined organic layers were dried over Na2SO4, concentrated under reduced pressure to give a residue, and mixed with H2O (10 mL) and ACN (1.00 mL). The mixture was then lyophilized to give the title compound (45.2 mg, 146 μmol, 32.3% yield, 98.4% purity) as an off-white solid. LC-MS: Rt = 0.885 min, m / z = 304.2 (M+H)+. HPLC: Rt = 2.111 min, 98.4% purity at 220 nm. 1H NMR:400MHz MeODδ:7.2-7.25(m,2H),7.11-7.17(m,3H),4.05-4.08(m,1H),3.78-3.86(m,2H),3.26-3.29(m,1H),3.11- 3.12(m,1H),2.58-2.62(m,2H),2.36-2.40(m,2H),1.56-1.63(m,2H),1.38-1.39(m,4H),1.33-1.36(m,8H). 13 C NMR: 400MHz MeODδ: 174,144,130,127,67.9,44.6,40.5,37.0,35.8,35.0,34.2,32.8,30.5,30.3,26.8)ppm.

[0263] Synthesis of 4-hydroxy-N-(5-phenylpentyl)piperidine-1-carboxamide (Formula 18)

[0264]

[0265] CDI (97.4 mg, 600 μmol) and TEA (152 mg, 1.50 mmol, 209 μL) were added to a solution of 5-phenylpentane-1-amine (100 mg, 500 μmol, HCl) in DMF (1.0 mL). The mixture was degassed, purged with N2 3 times, and stirred at 30 ° C under N2 for 0.5 hours. Piperidin-4-ol (60.7 mg, 600 μmol) was added and stirred at 30 ° C under N2 for 16 hours. The mixture was diluted with H2O (15 mL) and extracted with EtOAc (15 mL×3). The combined organic layers were washed with brine (10 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by HPLC (column: Waters Xbridge C18 150×50 mm×10 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 20%-50%, 10 min) to give the title compound (44.8 mg, 151 μmol, yield 30.2%, purity 98.0%) as an off-white solid. LCMS: Rt=0.860 min, m / z=291.3 (M+H)+. HPLC: Rt=2.165 min, purity 98.1% at 220 nm. 1H NMR:400MHz MeOD-d4δ:7.25-7.13(m,5H),3.79-3.75(m,3H),3.14-3.11(m,2H),3.03-2.99(m,2H),2.6 3-2.59(m,2H),1.80-1.66(m,2H),1.64-1.62(m,2H),1.52-1.41(m,2H),1.38-1.34(m,4H). 13 C NMR: 400MHz MeOD-d4δ: 160,143,130,129,127,68.4,42.8,41.9,36.9,35.1,32.6,31.3,27.6)ppm.

[0266] Synthesis of 4-hydroxy-N-(5-phenylpentyl)cyclohexane-1-carboxamide (Formula 26).

[0267]

[0268] To a solution of 4-hydroxycyclohexane-1-carboxylic acid (32.8 mg, 227 μmol) in DMF (1.0 mL) was added HOBt (36.9 mg, 273 μmol), EDCI (65.4 mg, 341 μmol), DIEA (88.2 mg, 682 μmol, 118 μL) and 5-phenylpentane-1-amine (50.0 mg, 250 μmol, HCl). The mixture was stirred at 30 ° C for 16 hours and purified by HPLC (column: Phenomenex Gemini-NX C18 75×30 mm×3 μm; mobile phase: [water (0.1% TFA)-ACN]; B%: 40%-50%, 7 minutes). The title compound (44.0 mg, 150 μmol, yield 66.0%, purity 98.7%) was obtained as an off-white solid. LC-MS: Rt = 0.847 min, m / z = 290.1 ​​(M+H)-. HPLC: Rt = 1.881 min, Rt = 1.922 min, purity 98.7% at 220 nm. 1 H NMR:400MHz MeOD-d4δ:7.25-7.11(m,5H),3.91-3.47(m,1H),3.17-3.13(m,2H),2.62-2.59(m,2H),1.99-1.97(m ,1H),1.76-1.65(m,2H),1.63-1.61(m,2H),1.53-1.50(m,2H),1.49-1.34(m,5H),1.33-1.20(m,3H). 13C NMR:400MHz MeOD-d4δ: (179,178,143,130,129,126,70.7,66.6,45.6,45.4,40.2,36.9,35.7,32.9,32.5,32.4,30.4,30.3,29.2,27.5,24.9)ppm.

[0269] Synthesis of (1r,4r)-4-hydroxy-N-(4-phenylbutoxy)cyclohexane-1-carboxamide (Formula 28A, diastereomer of Formula 28).

[0270]

[0271]

[0272] To a mixture of (4-bromobutyl)benzene (300 mg, 1.41 mmol) and 2-hydroxyisoindoline-1,3-dione (275 mg, 1.69 mmol) in DMF (10.00 mL) at 20°C was added K2CO3 (389 mg, 2.82 mmol). The mixture was stirred at 80°C for 1 hour to give (191 mg, 646 μmol, 45.9% yield). To a solution of 2-(4-phenylbutyloxy)isoindoline-1,3-dione (190 mg, 643 μmol) in DCM (10.0 mL) at 25°C was added NH2-NH2·H2O (322 mg, 6.43 mmol). The mixture was stirred for 2 hours to give O-(4-phenylbutyl)hydroxylamine (95.0 mg, 574 μmol, 89.3% yield). O-(4-phenylbutyl)hydroxylamine was mixed with (1r, 4r)-4-hydroxycyclohexane-1-carboxylic acid (124 mg, 862 μmol) in THF (10.0 mL) with HATU (327 mg, 862 μmol) and TEA (174 mg, 1.72 mmol, 3.00 mL) at 25 ° C. The mixture was stirred for 2 hours at 25 ° C. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by HPLC (neutral conditions, column: Waters Xbridge 150×25 mm×5 μm; mobile phase: [water (10 mM NH4HCO3)-ACN]; B%: 26%-56%, 10 min) to give the title compound (83.72 mg, 286 μmol, yield 49.7%, purity 99.6%) as a grayish-white solid. LCMS: RT=0.730min, m / z=292.2(M+H)+. HPLC: RT=1.803mins, 99.6% purity under 220nm. 1H NMR: 400MHz, DMSO-d6δ: 10.9-10.5(m,1H),7.28-7.25(m,2H),7.19-7.14(m,3H),4.63-4.52(m,1H),3.73-3.70(m,2H),3.34-3 .30(m,1H),2.59-2.56(m,2H),1.84-1.81(m,3H),1.64-1.62(m,4H),1.60-1.51(m,2H),1.43-1.28(m,2H),1.09-1.06(m,2H).

[0273] Synthesis of (1r,4R)-4-hydroxy-N-((1R,2R)-2-(3-phenylpropyl)cyclopropyl)cyclohexane-1-carboxamide (Formula 29A, diastereomer of Formula 29).

[0274]

[0275] To a solution of 4-phenylbutyraldehyde (3.34 g, 22.5 mmol) was added tert-butyl 2-(triphenyl-15-phosphinyl)acetate (10.1 g, 27.0 mmol) at 25°C under N2. The mixture was stirred for 12 hours to give tert-butyl (E)-6-phenylhex-2-enoate (3.54 g, 14.3 mol, 63.7% yield). To a mixture of BLAH iodomethane [(CH3)3SOI] (1.61 g, 7.31 mmol) in DMSO (10.0 mL) was added NaH (292 mg, 7.31 mmol) at 25°C under N2, and the mixture was stirred at 25°C for 1 hour. After 1 hour, (E)-6-phenylhex-2-enoic acid tert-butyl ester (1.50 g, 6.09 mmol) was added to the mixture and stirred for another 1 hour to give (1S, 2S)-2-(3-phenylpropyl)cyclopropane-1-carboxylic acid tert-butyl ester (790 mg, 3.03 mmol, 49.8% yield). At 25° C., TFA (14.1 g, 124 mmol, 9.19 mL) was added to a mixture of (1S, 2S)-2-(3-phenylpropyl)cyclopropane-1-carboxylic acid tert-butyl ester (790 mg, 3.03 mmol) in DCM (10.0 mL) and stirred for 1 hour to give (1S, 2S)-2-(3-phenylpropyl)cyclopropane-1-carboxylic acid (576 mg, 2.82 mmol, 92.9% yield). To a mixture of (1S,2S)-2-(3-phenylpropyl)cyclopropane-1-carboxylic acid (576 mg, 2.82 mmol) in toluene (10.0 mL) was added DPPA (776 mg, 2.82 mmol) and TFA (428 mg, 4.23 mmol) at 25°C under N2. The mixture was heated to 105°C and stirred for 2 hours to give (1S,2S)-2-(3-phenylpropyl)cyclopropane-1-amine (73.0 mg, 416 μmol, 14.7% yield). To a mixture of (1S,2S)-2-(3-phenylpropyl)cyclopropane-1-amine (73.0 mg, 416 μmol) and (1r,4r)-4-hydroxycyclohexane-1-carboxylic acid (72.1 mg, 500 μmol) in THF (10.0 mL) were added HATU (237 mg, 625 μmol) and TEA (361 mg, 3.57 mmol, 0.50 mL) at 25°C and stirred for 12 hours.The reaction mixture was concentrated under reduced pressure to give a residue, and purified by HPLC (TFA conditions, column: Phenomenex Synergi Polar-RP 100×25 mm×4 μm; mobile phase: [water (TFA)-ACN]; B%: 43%-63%, 7 min) to give the title compound (8.29 mg, 26.6 μmol, yield 6.38%, purity 96.6%) as a white solid. LCMS: RT=0.892 min, m / z=302.2 (M+H)+. HPLC: RT=2.309 mins, purity 96.6% at 220 nm. 1 H NMR: 400MHz, DMSO-d6δ: 7.72 (d, J = 4.0, 1H), 7.28-7.24 (m, 2H), 7.19-7.13 (m, 3H),4.51(d,J=4.4,1H),3.30-3.26(m,1H),2.60-2.56(m,2H),2.32-2.27(m,1 H),1.83-1.79(m,3H),1.65-1.60(m,4H),1.34-1.30(m,2H),1.20-1.19(m,2H ),1.07-1.04(m,2H),0.75-0.70(m,1H),0.51-0.49(m,1H),0.38-0.36(m,1H).

[0276] Synthesis of (1r,4r)-4-hydroxy-N-(2-(4-phenylbutyl)cyclopropyl)cyclohexane-1-carboxamide (Formula 30A, diastereomer of Formula 30).

[0277]

[0278] The title compound was synthesized as described in Scheme 1.

[0279]

[0280] Solution 1

[0281] Briefly, 5-phenylpentan-1-ol was converted to the corresponding aldehyde using Dess-Martin periodinane, and the crude aldehyde was converted to the corresponding tert-butyl-α,β-unsaturated ester using tert-butyl 2-(triphenyl-15-phosphinyl)acetate in an overall yield of ~75%. Cyclopropanation was then performed using Me3SOI in an overall yield of ~36%. The tert-butyl ester was cleaved using trifluoroacetic acid, and the crude cyclopropyl carboxylic acid was then converted to the corresponding BOC-protected amine using diphenylphosphoryl azide in tert-butanol in an overall yield of ~48%. The free amine was released using HCl gas in dioxane in a yield of ~91%, and then coupled with (1r,4r)-4-hydroxycyclohexane-1-carboxylic acid using EDCI to give the title compound in a yield of 50%. LCMS: RT = 0.521 min, m / z = 316.2 (M+H)+. HPLC: RT = 2.738 mins, purity 96.2% at 220 nm. 1 H NMR: 400MHz, DMSO-d6δ: 7.69 (d, J = 4.4Hz, 1H), 7.27-7.24 (m, 2H), 7.18-7.13 ( m,3H),4.51(d,J=4.4Hz,1H),3.30-3.26(m,1H),2.57-2.53(m,2H),2.32-2.31 (m,1H),1.89-1.80(m,3H),1.63-1.57(m,4H),1.37-1.31(m,6H),1.08-1.04(m ,2H),0.70-0.68(m,1H),0.48-0.46(dt,J=8.8,4.8Hz,1H),0.37-0.36(m,1H).

[0282] Synthesis of (1r,4r)-4-hydroxy-N-(3-(3-phenylpropyl)cyclobutyl)cyclohexane-1-carboxamide (Formula 31A, diastereomer of Formula 31).

[0283]

[0284] The title compound was synthesized in a similar manner to Formula 30A, except that 3-(3-phenylpropyl)cyclobutan-1-amine was prepared as an intermediate for coupling. 1 H NMR confirmed the identity of the product.

[0285] Synthesis of (1r,4S)-4-hydroxy-N-((1S,2S)-2-phenethoxycyclopropyl)cyclohexane-1-carboxamide (Formula 32A, diastereomer of Formula 32).

[0286]

[0287] To a mixture of ethyl (1S,2S)-2-phenethoxycyclopropane-1-carboxylate (440 mg, 1.88 mmol) in MeOH (5.00 mL), THF (5.00 mL) and H2O (2.00 mL) was added LiOH·H2O (157 mg, 3.76 mmol) at 25°C. The mixture was heated to 70°C and stirred for 2 hours to give (1S,2S)-2-phenethoxycyclopropane-1-carboxylic acid (284 mg, 1.38 mmol, yield 73.3%). To a mixture of (1S,2S)-2-phenethoxycyclopropane-1-carboxylic acid (264 mg, 1.28 mmol) in toluene (10.0 mL) at 25°C under N2 was added DPPA (352 mg, 1.28 mmol) and TFA (194 mg, 1.92 mmol, 1.50 equiv). The mixture was heated to 105°C and stirred for 2 hours to give (1S, 2S)-2-phenethoxycyclopropane-1-amine (54.0 mg, 304 μmol, yield 23.8%). To a mixture of (1S, 2S)-2-phenethoxycyclopropane-1-amine (47.0 mg, 265 μmol) and (1r, 4r)-4-hydroxycyclohexane-1-carboxylic acid (45.8 mg, 318 μmol) in THF (10.0 mL) was added HATU (151 mg, 397 μmol) and TEA (727 mg, 7.18 mmol, 1.00 mL) at 25°C and stirred for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue, and purified by HPLC (neutral conditions, column: Waters Xbridge 150×25 mm×5 μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 25%-55%, 10 min and TFA conditions, and column Phenomenex Synergi Polar-RP 100×25 mm×4 μm; mobile phase: [water (TFA)-ACN]; B%: 36%-56%, 7 min) to give the title compound (7.89 mg, 25.7 μmol, yield 9.69%, purity 98.8%) as a white solid. LCMS: RT=0.716 min, m / z=304.2 (M+H)+. HPLC: RT=1.709 mins, purity 98.8% at 220 nm. 1H NMR: 400MHz, DMSO-d6δ: 7.74 (d, J = 3.6, 1H), 7.29-7.25 (m, 2H), 7.23-7.1 6(m,3H),4.55(d,J=4.4,1H),3.77-3.66(m,2H),3.33-3.29(m,2H),3.07- 3.06(m,1H),2.81-2.77(m,2H),1.88-1.79(m,3H),1.64-1.60(m,2H),1. 33-1.30(m,2H),1.13-1.07(m,2H),0.84-0.82(m,1H),0.65-0.64(m,2H).

[0288] Synthesis of (1r,4r)-N-(2-(benzyloxy)cyclopropyl)-4-hydroxycyclohexane-1-carboxamide (Formula 33A, diastereomer of Formula 33).

[0289]

[0290] To a mixture of ethyl 2-(benzyloxy)cyclopropane-1-carboxylate (750 mg, 3.41 mmol) in MeOH (5.00 mL), THF (5.00 mL) and H2O (2.00 mL) was added LiOH·H2O (285 mg, 6.81 mmol) at 25°C. The mixture was heated to 70°C and stirred for 2 hours to give 2-(benzyloxy)cyclopropane-1-carboxylic acid (485 mg, 2.52 mmol, yield 74.1%). To a mixture of 2-(benzyloxy)cyclopropane-1-carboxylic acid (485 mg, 2.52 mmol) in toluene (10.0 mL) was added DPPA (694 mg, 2.52 mmol), TFA (382 mg, 3.78 mmol) at 25°C under N2. The mixture was heated to 105° C. and stirred for 2 hours to give 2-(benzyloxy)cyclopropane-1-amine (108 mg, 661 μmol, yield 26.2%). HATU (377 mg, 992 μmol) and TEA (1.81 g, 17.9 mmol, 2.50 mL) were added to a mixture of 2-(benzyloxy)cyclopropane-1-amine (108 mg, 661 μmol) and (1r, 4r)-4-hydroxycyclohexane-1-carboxylic acid (114 mg, 794 μmol) in THF (10.0 mL) at 25° C. and stirred for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue, and the title compound (5.97 mg, 20.1 umol, yield 3.05%, purity 97.8%) was obtained as a white solid by HPLC (TFA conditions, column: Phenomenex Synergi Polar-RP 100×25 mm×4 μm; mobile phase: [water (TFA)-ACN]; B%: 32%-52%, 7 min) and (neutral conditions, column: Waters Xbridge 150×25 mm×5 μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 21%-51%, 9 min). LCMS: RT=0.671 min, m / z=290.1 ​​(M+H)+. HPLC: RT=1.821 mins, purity 97.8% at 220 nm. 1H NMR: 400MHz, DMSO-d6δ: 7.76 (d, J = 3.2, 1H), 7.26-7.30 (m, 5H), 4.62-4.53 (m, 3H), 3.31-3.29 (m, 1H), 3.14-3.12 (m, 1H), 2.64- 2.63(m,1H),1.91-1.80(m,3H),1.64-1.62(m,2H),1.36-1.33(m,2H),1.09-1.05(m,2H),1.01-0.97(m,1H),0.71-0.70(m,1H).

[0291] Synthesis of (1r,4r)-4-hydroxy-N-(2-(3-phenylpropoxy)cyclobutyl)cyclohexane-1-carboxamide (Formula 34A, diastereomer of Formula 34).

[0292]

[0293]

[0294] To a mixture of ethyl 2-(3-phenylpropoxy)cyclopropane-1-carboxylate (870 mg, 3.50 mmol) in MeOH (5.00 mL), THF (5.00 mL) and H2O (2.00 mL) was added LiOH·H2O (294 mg, 7.01 mmol) at 25°C. The mixture was heated to 70°C and stirred for 2 hours to give 2-(3-phenylpropoxy)cyclopropane-1-carboxylic acid (690 mg, 3.13 mmol, yield 89.4%). To a mixture of 2-(3-phenylpropoxy)cyclopropane-1-carboxylic acid (690 mg, 3.13 mmol) in toluene (10.0 mL) was added DPPA (862 mg, 3.13 mmol), TFA (475 mg, 4.70 mmol) at 25°C under N2. The mixture was heated to 105° C. and stirred for 2 hours to give 2-(3-phenylpropoxy)cyclopropane-1-amine (154 mg, 805 μmol, yield 25.7%). To a mixture of 2-(3-phenylpropoxy)cyclopropane-1-amine (154 mg, 805 μmol) and (1r, 4r)-4-hydroxycyclohexane-1-carboxylic acid (139 mg, 966 μmol) in THF (5.00 mL) was added HATU (459 mg, 1.21 mmol) and TEA (727 mg, 7.18 mmol, 1.00 mL) at 25° C. and stirred for 12 hours. The reaction mixture was concentrated under reduced pressure to give a residue, which was purified by HPLC (TFA conditions, column: Phenomenex Synergi Polar-RP 100×25 mm×4 μm; mobile phase: [water (TFA)-ACN]; B%: 41%-61%, 7 min) and (neutral conditions, column: Waters Xbridge 150×25 mm×5 μm; mobile phase: [water (NH4HCO3)-ACN]; B%: 31%-61%, 10 min) to give the title compound (7.29 mg, 22.5 μmol, yield 2.80%, purity 98.1%) as an off-white solid. LCMS: RT=0.830 min, m / z=318.2 (M+H)+. HPLC: RT=1.814 mins, purity 98.1% at 220 nm. 1H NMR: 400MHz, DMSO-d6δ: 7.71 (d, J = 3.6, 1H), 7.28-7.25 (m, 2H), 7.19-7.16 (m, 3H),4.52(d,J=4.4,1H),3.54-3.45(m,2H),3.43-3.30(m,1H),3.07-3.06(m,1 H),2.59-2.55(m,3H),1.89-1.82(m,1H),1.80-1.76(m,4H),1.73-1.61(m,2H ),1.34-1.30(m,2H),1.08-1.05(m,2H),0.90-0.87(m,1H),0.65-0.64(m,1H).

[0295] Mitofusin Activity and In Vitro Pharmacology. Table 1 below summarizes the biological activities of compounds of Formula 7-10, 18, 24, 26, 28A, and 29A-34A, compared to the mitofusin activator of Formula 1.

[0296] Table 1

[0297]

[0298] As shown, compounds having Formulae 7-10 and containing an endocyclically bonded amide nitrogen atom exhibit unexpectedly dramatic increases in PAMPA values ​​compared to compounds having Formula 1. Some of these compounds also retain low EC 50 The corresponding urea analog of the compound of Formula 7 (i.e., the urea compound of Formula 18) has an EC 50 The corresponding amide analogs having the amide nitrogen atom located on the other side of the carbonyl group (i.e., amides of Formula 26) exhibited EC 50 and PAMPA values ​​and the EC of the compound having formula 1 50 In some cases, compounds of Formula 28A-34A (each containing a modification of the linker between the amide nitrogen atom and the phenyl group in the compound of Formula 26) maintain low EC 50 , but with the exception of compounds of formula 30A and 31A, there was no improvement in the PAMPA assay.

[0299] Unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by embodiments of the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0300] One or more exemplary embodiments including various features are presented herein. For the sake of clarity, all features of physical implementation are not described or shown in this application. It should be understood that in the development of physical implementations in conjunction with the embodiments of the present invention, many implementation-specific decisions must be made to achieve the developer's goals, such as compliance with system-related, business-related, government-related and other constraints that vary with the specific implementation and time. Although the developer's efforts may be time-consuming, such efforts will be routine undertakings for those of ordinary skill in the art and benefit from the present disclosure.

[0301] Although various systems, tools, and methods are described herein in terms of "comprising" various components or steps, the systems, tools, and methods may also "consist essentially of" or "consist of" the various components and steps.

[0302] As used herein, the phrase "at least one of" preceding a series of items, and the terms "and" or "or" used to separate any items, modify the list as a whole, rather than modifying each member of the list (i.e., each item). The phrase "at least one of" allows for a meaning that includes at least one of any one item, and / or at least one of any combination of items, and / or at least one of each item. For example, the phrase "at least one of A, B, and C" or "at least one of A, B, or C" each refers to only A, only B, or only C; any combination of A, B, and C; and / or at least one of each of A, B, and C.

[0303] Therefore, the disclosed systems, tools and methods are well suited to achieve the mentioned purposes and advantages and the purposes and advantages inherent therein. The specific embodiments disclosed above are exemplary only, because the teachings of the present disclosure can be modified and practiced in different but equivalent ways, which is obvious to those skilled in the art who benefit from the teachings herein. In addition, except as described in the claims below, it is not intended to limit the details of the construction or design shown herein. Therefore, it is obvious that the specific exemplary embodiments disclosed above can be changed, combined or modified, and all these changes are considered to be within the scope of the present disclosure. In the absence of any element not specifically disclosed herein and / or any optional element disclosed herein, the systems, tools and methods disclosed herein illustratively can be appropriately practiced. Although systems, tools and methods are described in terms of "comprising", "containing" or "including" various parts or steps, these systems, tools and methods can also be "essentially composed of various parts and steps" or "composed of various parts and steps". All numbers and ranges disclosed above can vary to a certain extent. Whenever a numerical range with a lower limit and an upper limit is disclosed, any number and any included range falling within the range are specifically disclosed. In particular, each value range disclosed herein (in the form of "about a to about b", or equivalently, "about a to b", or equivalently, "about ab") should be understood to set forth each numerical value and range covered within the broader value range. In addition, unless otherwise explicitly and clearly defined by the patentee, the terms in the claims have their plain, ordinary meaning. In addition, the indefinite articles "a" or "an" used in the claims are defined herein to mean one or more than one element that they introduce. If there is any conflict in the use of a word or term in this specification with the use of a word or term in one or more patents or other documents that may be incorporated herein by reference, the definition consistent with this specification should be adopted.

Claims

1. A composition comprising: A mitochondrial fusion protein activator having a structure represented by the following formula: any stereoisomer thereof or any pharmaceutically acceptable salt thereof; in: G is N or CH, and A is an optionally substituted 5- or 6-membered cycloalkyl or heterocycloalkyl ring; X is (CH2)3, OCH2CH2, CH2OCH2, CH2CH2O, Cyc, CH2Cyc、NR 1 (CH2)3、NR 1 OCH2CH2、NR 1 CH2OCH2、 NR 1 CH2CH2O or NR 1 Cyc; Where R 1 is H or C1-C6 alkyl, and Cyc is 1,2-cyclopropyl, 1,2-cyclobutyl, 1,3-cyclobutyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 1,2-cyclohexyl, 1,3-cyclohexyl or 1,4-cyclohexyl; Z is (CH2) n or (CH2) n1 O(CH2) n2 ; wherein n is an integer ranging from 1 to 5, n1 is an integer ranging from 0 to 4, n2 is an integer ranging from 0 to 4, and n1+n2=n-1; and R 2 is an optionally substituted aryl or heteroaryl group.

2. The composition of claim 1, wherein R 2 is an optionally substituted phenyl group.

3. The composition of claim 1, wherein G is N and A represents an optionally substituted piperidinyl, piperazinyl, morpholinyl or pyrrolidinyl group.

4. The composition of claim 3, wherein the mitochondrial fusion protein activator has a structure represented by the following formula: or any stereoisomer thereof; Where J is a bond, CH(hal), CHOR 3 , CHR 4 , CHNR 4 R 5 , O or NR 4 , and Q is an optional substituent; Where hal is a halogen, R 3 is H or C1-C6 alkyl, and R 4 and R 5 are independently H, C1-C6 alkyl or C1-C6 acyl.

5. The composition of claim 4, wherein J is CHOR 3 or CHR 4 .

6. The composition of any one of claims 3-5, wherein X is (CH2)3, 1,2-cyclopropyl, 1,2-cyclobutyl or 1,3-cyclobutyl.

7. The composition of claim 6, wherein Z is (CH2) n or O(CH2) n-1 , and n is an integer ranging from 2 to 5.

8. The composition of claim 6, wherein A is 4-hydroxypiperidinyl.

9. The composition of claim 6, wherein R 2 is an optionally substituted phenyl group.

10. The composition of any one of claims 3 to 5, wherein the mitochondrial fusion protein activator has a structure represented by the following formula: or any stereoisomer thereof.

11. The composition of any one of claims 3 to 5, wherein X is NR 1 (CH2)3、NR 1 (1,2-cyclopropyl), NR 1 (1,2-cyclobutyl) or NR 1 (1,3-cyclobutyl).

12. The composition of claim 11, wherein Z is (CH2) n or O(CH2) n-1 , and n is an integer ranging from 1 to 4.

13. The composition of claim 6, wherein A is 4-hydroxypiperidinyl.

14. The composition of claim 6, wherein R 2 is an optionally substituted phenyl group.

15. The composition of any one of claims 3 to 5, wherein the mitochondrial fusion protein activator has a structure represented by the following formula: or any stereoisomer thereof.

16. The composition of claim 1 wherein G is CH and A represents an optionally substituted piperidinyl, pyrrolidinyl, tetrahydropyranyl, tetrahydrofuranyl, cyclopentyl or cyclohexyl group.

17. The composition of claim 16, wherein the mitochondrial fusion protein activator has a structure represented by the following formula: or any stereoisomer thereof; Where J is a bond, CH(hal), CHOR 3 , CHR 4 , CHNR 4 R 5 , O or NR 4 , and Q is an optional substituent; Where hal is a halogen, R 3 is H or C1-C6 alkyl, and R4 and R 5 are independently H, C1-C6 alkyl or C1-C6 acyl.

18. The composition of claim 17, wherein J is CHOR 3 or CHR 4 .

19. The composition of any one of claims 16 to 18, wherein X is NR 1 (CH2)3、NR 1 (1,2-cyclopropyl), NR 1 (1,2-cyclobutyl) or NR 1 (1,3-cyclobutyl).

20. The composition of claim 19, wherein Z is (CH2) n or O(CH2) n-1 , and n is an integer ranging from 2 to 4.

21. The composition of claim 19, wherein A is 4-hydroxycyclohexyl.

22. The composition of claim 19, wherein R 2 is an optionally substituted phenyl group.

23. The composition of any one of claims 16-18, wherein the mitochondrial fusion protein activator has a structure represented by the following formula: or any stereoisomer thereof.

24. The composition of any one of claims 1-5 or 16-18, further comprising: a pharmaceutically acceptable excipient.

25. A method comprising: Administering a therapeutically effective amount of the composition of any one of claims 1-5 or 16-18, any stereoisomer thereof, or any pharmaceutically acceptable salt thereof to a subject suffering from or suspected of suffering from a mitochondrial-related disease, disorder, or condition.

26. The method of claim 25, wherein the mitochondrial-related disease, disorder or condition is a peripheral nervous system (PNS) or central nervous system (CNS) genetic or non-genetic disorder, physical injury and / or chemical injury.

27. The method of claim 26, wherein the PNS or CNS disorder is one or more conditions selected from the group consisting of: chronic neurodegenerative conditions in which mitochondrial fusion, adaptation or trafficking is impaired; diseases or conditions associated with mitochondrial fusion protein-1 (MFN1) or mitochondrial fusion protein-2 (MFN2) dysfunction; diseases associated with mitochondrial fragmentation, dysfunction and / or movement disorders; degenerative neuromuscular conditions; Charcot-Marie-Doucet disease; amyotrophic lateral sclerosis; Huntington's disease; Alzheimer's disease; Parkinson's disease; hereditary motor and sensory neuropathies; autism; autosomal dominant optic atrophy (ADOA); muscular dystrophy; Lou Gehrig's disease; cancer; mitochondrial myopathy; diabetes mellitus and deafness (DAD); Leber's hereditary optic neuropathy (LHON); Leigh's syndrome; subacute sclerosing encephalopathy; Neuropathy, ataxia, retinitis pigmentosa, and ptosis (NARP); myoneurogenic gastrointestinal encephalopathy (MNGIE); myoclonic epilepsy with red ragged fibers (MERRF); mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like symptoms (MELAS); mtDNA depletion; Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE); dysautonomia mitochondrial myopathy; mitochondrial channelopathy; Pyruvate dehydrogenase complex deficiency (PDCD / PDH); diabetic neuropathy; chemotherapy-induced peripheral neuropathy; crush injury; spinal cord injury (SCI); traumatic brain injury; stroke; optic nerve injury; disorders involving axonal disconnection; and any combination thereof.